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II 
LUNG CANCER 
 
Lung cancer is the leading cause of cancer deaths in the United States and worldwide. The 
two major forms of lung cancer are non–small cell lung cancer (NSCLC - about 85% of all 
lung cancers) and small-cell lung cancer (SCLS - about 15%). This classification is based 
upon the microscopic appearance of the tumor cells themselves. These two types of cancers 
grow and spread in different ways and may have different treatment options, so a distinction 
between these two types is important. Despite advances in early detection and standard 
treatment, non-small cell lung cancer is often diagnosed at an advanced stage and has a 
poor prognosis. The treatment and prevention of lung cancer are the major unmet needs that 
can probably be improved by a better understanding of the molecular origins and evolution of 
the disease. Non–small-cell lung cancer can be divided into three major histologic subtypes: 
squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer. Smoking is a major 
risk factor of all types of lung cancer but is most strongly linked with small-cell lung cancer 
and squamous-cell carcinoma; adenocarcinoma is the most common type in patients who 
have never smoked. (1) 
SCLC is the most aggressive and rapidly growing of all lung cancers. SCLC metastasize 
rapidly to many sites within the body and are most often discovered after they have spread 
extensively. Referring to a specific cell appearance often seen when examining samples of 
SCLC under the microscope, these cancers are sometimes called oat cell carcinomas. 
Metastatic cancers from other primary tumors in the body are often found in the lung. Tumors 
from anywhere in the body may spread to the lungs either through the bloodstream, through 
the lymphatic system, or directly from nearby organs. Metastatic tumors are most often 
multiple, scattered throughout the lung, and concentrated in the peripheral rather than central 
areas of the lung. (2) 
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Figure 1. Pathogenesis of lung cancer: targeting a specific anatomical compartment. Lung cancer is one of few 
malignancies in which the major histological types arise in different anatomical compartments of the organ. The 
major function of the lungs is respiratory exchange, and inhaled air is conducted to the alveoli (the small sacs in 
which gaseous exchange occurs) through a network of branching tubes (bronchi and bronchioles). The larger 
tubes, having muscular walls reinforced with cartilage are the bronchi, while smaller tubes (< 1 mm in diameter) 
that hav incomplete muscular walls and lack cartilage are called bronchioles, and they connect to the alveoli. The 
putative stem cell of the bronchus is the basal cell, which is believed to give rise to the differentiated ciliated, 
mucous and neuroendocrine cells. The terminal bronchioles and alveoli are believed to share a common stem 
cell, and a putative stem cell has recently been identified in the mouse. However, the peripheral airway stem cell 
is difficult to identify morphologically, and the cells capable of dividing in these locations are the Clara cells (in the 
bronchioles) and the surfactant secreting type II pneumocytes (in the alveoli). The secretory products of 
peripheral airway cells include Clara cell protein 10 (CC10) and surfactant (from type II pneumocytes). Thus, 
region-specific stem cell niches function to maintain epithelial diversity. Lung cancer may be considered to arise 
from either the central airway compartment (predominantly SCLC and squamous cell carcinoma) or from the 
peripheral airway compartment (predominantly adenocarcinoma). (3) 
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Staging of lung cancer 
The stage of a cancer refers to the extent to which a cancer has spread in the body. Staging 
involves both evaluation of a cancer's size as well as the presence or absence of metastases 
in the lymph nodes or in other organs. Staging is important for determining how a particular 
cancer should be treated, since lung-cancer therapies are geared toward specific stages. 
Staging of a cancer is also critical in estimating the prognosis of a given patient, with higher-
stage cancers generally having a worse prognosis than lower-stage cancers. NSCLC are 
assigned a stage from I to IV in order of severity: 
• In stage I, the cancer is confined to the lung. 
• In stages II and III, the cancer is confined to the chest (with larger and more invasive tumors 
classified as stage III). 
• Stage IV cancer has spread from the chest to other parts of the body. 
SCLC are staged using a two-tiered system: 
• Limited-stage SCLC refers to cancer that is confined to its area of origin in the chest. 
• In extensive-stage SCLC, the cancer has spread beyond the chest to other parts of the body. 
The TNM staging system for lung cancer provides a consistent reproducible description of 
the extent of anatomic involvement. This is achieved by defining the characteristics of 
primary tumor (T), regional lymph node involvement (N), and metastasis (M). (2) 
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Figure 2. The chart lists the comparative characteristics of primary tumor in the vertical columns (including size, 
endobronchial location, local invasion, and other characteristics). The horizontal columns refer to the lymph node 
involvement. The different stages are color coded and can be found at the intersection of appropriately matched 
horizontal and vertical columns. Stages with unique characteristics such as stages 0 and IV are defined in 
separate boxes. The most recently adopted revisions of TNM staging are reflected in this chart, which include the 
following: division of stage I into stages IA and IB; splitting of stage II into stage IIA and stage IIB; shifting of 
T3N0M0 from stage IIIA to stage IIB; and classification of multiple tumor nodules (T4 if the satellite nodule(s) are 
in the same lobe or M1 if the intrapulmonary ipsilateral nodule(s) are in the nonprimary tumor lobe(s)). (4) 
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Lung cancer treatment and prognosis 
Treatment for lung cancer can involve surgical removal of the cancer, chemotherapy, or 
radiation therapy, as well as combinations of these treatments. The decision about which 
treatments will be appropriate for a given individual must take into account the localization 
and extent of the tumor as well as the overall health status of the patient. 
 
Surgery. Surgical removal of the tumor is generally performed for limited-stage (stage I or 
sometimes stage II) NSCLC and is the treatment of choice for cancer that has not spread 
beyond the lung. About 10%-35% of lung cancers can be removed surgically, but removal 
does not always result in a cure, since the tumors may already have spread and can recur at 
a later time.  
 
Radiation. Radiation therapy may be employed as a treatment for both NSCLC and SCLC. 
Radiation therapy uses high-energy X-rays or other types of radiation to kill dividing cancer 
cells. Radiation therapy may be given as curative therapy, palliative therapy (using lower 
doses of radiation than with curative regimens), or as adjuvant therapy in combination with 
surgery or chemotherapy. Combining radiation therapy with chemotherapy can further 
increase the chances of survival when chemotherapy is administered. External radiation 
therapy can generally be carried out on an outpatient basis, while internal radiation therapy 
requires a brief hospitalization. A person who has severe lung disease in addition to a lung 
cancer may not be able to receive radiotherapy to the lung.  
 
Chemotherapy. Both NSCLC and SCLC may be treated with chemotherapy. Chemotherapy 
refers to the administration of drugs that stop the growth of cancer cells by killing them or 
preventing them from dividing. Chemotherapy may be given alone, as an adjuvant to surgical 
therapy, or in combination with radiotherapy. While a number of chemotherapeutic drugs 
have been developed, the class of drugs known as the platinum-based drugs have been the 
most effective in treatment of lung cancers. Chemotherapy is the treatment of choice for  
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most SCLC, since these tumors are generally widespread in the body when they are 
diagnosed. Only half of people who have SCLC survive for four months without 
chemotherapy. With chemotherapy, their survival time is increased up to four- to fivefold. 
Chemotherapy alone is not particularly effective in treating NSCLC, but when NSCLC have 
metastasized, it can prolong survival in many cases. Unfortunately, the drugs used in 
chemotherapy also kill normally dividing cells in the body, resulting in unpleasant side 
effects.  
 
Targeted therapy. The discovery that signaling by the epidermal growth factor receptor 
(EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in 
anticancer therapy. Two different types of EGFR-targeted therapeutic agents were 
subsequently developed: mAbs, such as cetuximab and panitumumab, which target the 
extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal 
transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib 
(Tarceva), which target the intracellular tyrosine kinase domain of the EGFR. (5) This protein 
is found at abnormally high levels on the surface of some types of cancer cells, including 
many cases of non-small cell lung cancer. Other attempts at targeted therapy include 
antiangiogenesis drugs, which block the development of new blood vessels within a cancer. 
Without adequate blood vessels to supply oxygenated blood, the cancer cells will die. The 
antiangiogenic drug bevacizumab (Avastin) has recently been found to prolong survival in 
advanced lung cancer when it is added to the standard chemotherapy regimen (2). Another 
example of targeted therapy is represented by the use of the Tumour necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL), which is a potent stimulator of apoptosis. One of 
the most interesting aspects of this molecule is that tumour cells are significantly more 
sensitive to TRAIL-induced apoptosis than normal cells. Although the molecular basis for the 
tumour-selective activity of TRAIL remains to be fully defined, the TRAIL pathway is an 
attractive therapeutic target for the treatment of cancer. In addition to triggering a pro-
apoptotic signal through activation of caspases, TRAIL can activate diverse intracellular  
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signalling pathways involving NFκB, phosphoinositoide 3-kinase (PI3K) and mitogen 
activated protein kinase (MAPK)n family proteins that can stimulate cell survival and 
proliferation. TRAIL is an important immune effector molecule in the surveillance and 
elimination of developing tumours. Moreover, genetic lesions in various components of the 
TRAIL pathway have been found in human tumour samples, suggesting that inactivation of 
the TRAIL pathway and/or escape from TRAIL-mediated immunosurveillance might have an 
important role in tumour onset and progression. In preclinical trials, recombinant forms of 
TRAIL and agonistic anti-TRAIL receptor antibodies can have single-agent activity against 
TRAIL-sensitive tumour cells in vitro and in vivo. These agents can synergize with 
chemotherapeutic drugs and novel molecular therapeutic agents to more effectively kill 
TRAIL-sensitive tumour cells and TRAIL-resistant tumours. Early-phase clinical trials using 
recombinant TRAIL and agonistic anti-TRAIL receptor antibodies indicate that these agents 
can be delivered safely and are generally well-tolerated. Although some objective anti-
tumour responses have been reported with these agents as monotherapies, they probably 
hold greater  promise for further clinical development when used in combination with other 
cancer treatments. (6) 
 
Prognosis of lung cancer. SCLC has the most aggressive growth of all lung cancers, with a 
median survival time of only two to four months after diagnosis when untreated. However, 
SCLC is also the type of lung cancer most responsive to radiation therapy and 
chemotherapy. In non-small cell lung cancer (NSCLC), results of standard treatment are 
generally poor in all but the most localized cancers that can be surgically removed. However, 
in stage I cancers that can be completely removed, five-year survival approaches 75%. 
Radiation therapy can produce a cure in a small minority of patients with NSCLC and leads 
to relief of symptoms in most patients. In advanced-stage disease, chemotherapy offers 
modest improvements in survival time, although overall survival rates are poor. The overall 
prognosis for lung cancer is poor when compared with some other cancers. Survival rates for  
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lung cancer are generally lower than those for most cancers, with an overall five-year 
survival rate for lung cancer of about 16% compared to 65% for colon cancer, 89% for breast 
cancer, and over 99% for prostate cancer (2). 
 
Risk factors 
Environmental tobacco smoke. The causal relationship between smoking and lung cancer is 
well established with a 10- to 20-fold increased risk of lung cancer in smokers compared with 
never smokers. Given the link between active smoking and lung cancer, the association of 
environmental tobacco smoke (ETS) and lung cancer risk has been widely studied. ETS is a 
mixture of sidestream smoke released by the burning tip of the cigarette or other smoking 
device (such as a cigar or pipe) and mainstream smoke exhaled by the smoker. Sidestream 
smoke is the main component of ETS, and although diluted in air, consists largely of the 
same toxic substances and carcinogens that are inhaled by the active smoker, although the 
proportions of the different carcinogens may vary. Even though the dose of carcinogens from 
ETS is far less than from smoking, urinary metabolites of tobacco-specific carcinogens such 
as NNK are detectable in nonsmokers exposed to ETS, providing biological evidence for a 
role of ETS in lung cancer development.  
 
Radon. Radon is a radioactive gas produced from the decay of naturally occurring uranium in 
rocks and soil. Although chemically inert, radon decays into active products (‘radon progeny’) 
that attach themselves to particulate matter in the air and are inhaled, where they adhere to 
the respiratory epithelium.  
 
Hormonal factors. The higher proportion of lung cancer in female never smokers compared 
with male never smokers suggests a possible role for gender-dependent hormones in the 
development of lung cancer. Several studies have provided evidence supporting a biological 
role for oestrogen in lung carcinogenesis by direct promotion of cell proliferation. Oestrogen 
receptors (Erα and ERβ) are expressed in healthy lung tissue and lung tumours in both men  
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and women, and the data are inconsistent as to whether ER expression is biased to any 
gender. ERβ appears to be expressed more frequently than ERα in lung tissue, and its 
expression in NSCLC tumours is associated with improved survival, whereas the expression 
of ERα is a poor prognostic factor. In vitro studies have also shown that oestrogens stimulate 
the proliferation of NSCLC cells through oestrogen receptor-mediated signalling, whereas 
anti-oestrogens inhibit growth. In addition, oestrogens can potentially alter the metabolic 
activation of carcinogens such as PAHs, thus promoting carcinogenesis. 
 
Genetic factors. Inter-individual variations in the ability to metabolize carcinogens might 
contribute to differences in susceptibility to lung cancer. Genetic epidemiological studies 
have suggested that individuals with cytochrome P450 1A1(CYP1A1) polymorphisms (I462V) 
and/or a homozygous deletion of glutathione S‑transferase (GSTM1) are at increased risk of 
lung cancer, although other studies have found no association. Pooled analyses of case–
control studies of CYP1A1 and GSTM1 polymorphisms have found that the CYP1A1‑I462V 
polymorphism is associated with a twofold to threefold increased risk of lung cancer in 
Caucasian (but not in Asian) never smokers with no significant effect of the GSTM1-null 
genotype. However, a combined effect of CYP1A1‑I462V and GSTM1-null variants has been 
observed, with a greater than fourfold increased risk of lung cancer with the combination 
compared with those with two non-variant genotypes, suggesting possible interactions 
between the phase I and phase II enzymes. Differences in DNA repair capacity might also 
contribute to susceptibility to lung cancer, with the underlying hypothesis that individuals with 
lower capacity to repair DNA have a higher risk of lung cancer from DNA-damaging 
carcinogens. Polymorphisms in DNA repair genes involved in base excision repair (XRCC1 
and OGG1), nucleotide excision repair (ERCC1, ERCC2 and XPA), DNA double-strand 
break repair (XRCC3) and mismatch repair pathways (MLH1 and MSH2) have been studied 
in association with lung cancer risk. (3) 
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Molecular basis of lung cancer 
Clonal Evolution. Changes in certain genes (e.g., proinflammatory interleukin-8 [IL8] and 
some DNA-repair genes) occur in nonmalignant lung tissue of smokers and patients with 
lung cancer, a finding consistent with diffuse tissue injury. These changes probably precede 
epithelial clonal evolution, an important element of the molecular origins of lung and other 
cancers. Patches of clonally related cells, or clonal patches containing 40,000 to 360,000 
cells, have been mapped in the lung. The size and number of subclones in a clonal patch 
may contribute to the cancer risk. 
Early events in the development of non–small cell lung cancer include loss of heterozygosity 
at chromosomal region 3p21.3 (site of RASSF1A, a member of the Ras association domain 
family, and FUS1), 3p14.2 (FHIT, a fragile histidine triadgene), 9p21 (p16), and 17p13 (p53). 
All these genes are tumor-suppressor genes. Loss-of-heterozygosity patterns in squamous-
cell carcinoma and adenocarcinoma differ (e.g., chromosome 3p deletions are much more 
extensive in squamous cell carcinoma). Clonal patches with methylation of promoter regions 
of genes (epigenetic changes), p53 mutation, EGFR mutation, c-Myc amplification, loss of 
heterozygosity, and microsatellite instability can occur in normal tissue surrounding non–
small-cell lung tumors and may be associated with a greater risk of recurrence and second 
primary tumors. These findings suggest that in the future molecular analyses of surgical 
margins may help identify patients most likely to benefit from adjuvant therapy. (1) 
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Figure 3. Molecular evolution of Lung Cancer. Environmental factors, such as tobacco smoke, and genetic 
susceptibility interact to influence carcinogenesis. Factors that are unrelated to smoking — including genetic, 
hormonal, and viral (e.g., human papillomavirus) factors — have been suggested. Tissue injury (e.g., from 
tobacco smoke, reflected in the discolored smoking-related lungs) initially occurs in the form of genetic and 
epigenetic changes (e.g., mutations, loss of heterozygosity, and promoter methylation) and global transcriptome 
changes (e.g., inflammation and apoptosis pathways). These changes can persist long term and eventually lead 
to aberrant pathway activation and cellular function (e.g., deregulated proliferation and apoptosis) to produce 
premalignant changes, including dysplasia and clonal patches. Additional changes can result in 
angiogenesis, invasion and early-stage cancer, and advanced cancer and metastasis. Many molecular changes 
in earliest-stage cancer also occur in advanced disease. Premalignant patches contain clones and subclones 
(inset), which can involve loss of heterozygosity, microsatellite instability, and mutations (e.g., in p53 and 
epidermal growth factor receptor [EGFR]). Lung cancers unrelated and related to smoking have strikingly different 
molecular profiles, including those of mutations in p53, KRAS, EGFR, and HER2. Smoking-related patches and 
primary cancers (usually squamous-cell carcinoma and small-cell lung cancer) most often develop in the central 
airway. Most tumors that are not related to smoking are adenocarcinomas and develop in the peripheral airways. 
Molecular markers can signify risk (in people without cancer), prognosis (outcome independent of treatment), and 
sensitivity to treatment through predictive markers. Such stage-specific markers can span the course of disease 
from its early stages through its late stages. They also can help define mechanisms of resistance to therapy. (1) 
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EGFR Family. The EGFR protein belongs to a family of four surface receptor tyrosine  
kinases and is overexpressed in many cancers, including about 50% of lung cancers. On 
binding to one of several ligands, EGFR forms homodimers or heterodimers with other family 
members, initiating a cascade of signaling events that trigger anti-apoptotic signaling, 
proliferation, angiogenesis, invasion and metastasis. These multiple effects are initiated by 
the activation of three major pathways: the Akt pathway that leads to survival through the 
inhibition of apoptosis; activation of the Ras–mitogen-activated protein kinase (MAPK) 
pathway that leads to increased proliferation; and STAT signalling with effects on many other 
functions. These observations led to the development and widespread clinical testing of 
small-molecule tyrosine kinase inhibitors (TKIs) including erlotinib (Tarceva) and gefitinib 
(Iressa). Although these inhibitors had modest or no effects in most NSCLC cases, dramatic 
responses were observed in some patients. Subsequently, mutations in the tyrosine kinase 
domain of EGFR associated with drug sensitivity and treatment response were identified. (3) 
Preclinical and clinical data suggest that EGFR mutations are early events in the 
development of non–small-cell lung cancer. EGFR mutations, including those involving 
exons 18, 19, and 20 and L858R, can transform fibroblasts and lung epithelial cells. 
Deinduction of mutant EGFR expression led to regression of tumors, suggesting the need for 
persistent mutant EGFR activity for continued tumor survival. HER2 mutations and 
amplification have been identified in patients with lung adenocarcinoma. The frequency of 
such mutations is less than 5%, and the frequency of such amplification is 5 to 10%. HER2 
kinase domain mutations (in-frame insertions in exon 20) and EGFR kinase domain 
mutations have similar associations with female sex, nonsmoking status, and Asian 
background in patients with adenocarcinoma. HER2 amplification is associated with 
sensitivity to inhibitors of the EGFR tyrosine kinase; HER2 mutations are associated with 
resistance to such inhibitors but also with sensitivity to HER2-targeted therapy. HER3 kinase 
domain mutations have not been detected in patients with non–small-cell lung cancer. 
Mutations in the HER4 kinase domain were found in 2 to 3% of Asian patients with this  
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disease, with a possible association with male sex and smoking. (1) 
 
KRAS mutations. Ras proteins function downstream of the EGFR signalling pathway to 
mediate cell proliferation. Oncogenic missense mutations in KRAS result in the loss of 
intrinsic GTPase activity that is required to return Ras proteins to their inactive, GDP-bound 
form. Therefore, the intrinsic negative-feedback control of Ras activity is lost, leaving the 
mutated Ras constitutively activated. Several distinctive features characterize KRAS 
mutations in lung cancer. (3) Activating KRAS mutations are limited to non–small-cell lung 
cancer (predominantly adenocarcinomas), virtually mutually exclusive of mutations in the 
EGFR and HER2 kinase domains, and associated with resistance to EGFR inhibitors 
(tyrosine kinase inhibitors and cetuximab) and chemotherapy. Most KRAS mutations in lung 
adenocarcinoma are smoking-related G→T transversions (substitutions  of a purine for a 
pyrimidine) and affect exon 12 (in 90% of patients) or exon 13. Transversions (smokers) and 
transitions (nonsmokers) also have been reported for p53 mutations in lung adenocarcinoma. 
KRAS mutations appear to be an early event (e.g., detectable in the 
preinvasive lesions of atypical adenomatous hyperplasia and bronchoalveolar carcinoma) 
that precedes smoking-related lung adenocarcinoma. They generally mark a poor prognosis. 
(1) Further evidence supporting this gene’s role in the pathogenesis of lung cancer comes 
from transgenic mice bearing a mutated KRAS and in which multifocal atypical adenomatous 
hyperplasia and adenocarcinoma develop. (7)  
 
PI3K–Akt–mTOR. The pathway consisting of PI3K, Akt, and mammalian target of rapamycin 
(mTOR), which is downstream of EGFR, is activated early in lung carcinogenesis. (8) Akt is 
also overexpressed in bronchial dysplasia. Inhibition of Akt can induce apoptosis of human 
premalignant and malignant lung cells and prevent lung carcinogenesis in an animal model. 
An mTOR inhibitor can block malignant progression of atypical adenomatous hyperplasia 
lesions in the KRas mouse model.  Since mTOR drives tumorigenesis in part through 
macrophages, a prominent component of the tumor microenvironment, the antitumor effect of  
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mTOR inhibition requires the tumor microenvironment. There is mutation or amplification of  
PIK3CA, which encodes the PI3K catalytic subunit, in a subgroup of non–small-cell lung 
tumors, especially squamous-cell carcinoma, in association with increased PI3K activity and 
Akt expression. (1) 
 
TP53 gene. The tumour suppressor p53 (encoded by TP53) has multiple functions, but 
mainly acts as a transcription factor for a large number of target genes. Downstream effects 
include the regulation of apoptosis and DNA damage responses. Mutations in TP53 are one 
of the most frequent changes identified in human tumour cells, and the common mutations 
(usually in the DNA binding domains of the gene) lead to the generation of mutant forms with 
altered amino acid sequences that lack DNA binding activity. (9) 
 
Methylation, allelic loss and gene silencing. Aberrant methylation of promoter CpG islands 
might result in gene silencing (through chromatin remodelling), and is a frequent mechanism 
of tumour-suppressor gene inactivation in cancer. Inactivation of one allele of a tumour-
suppressor gene is often accompanied by allelic loss of the other allele, resulting in the ‘two-
hit’ loss needed to inactivate most tumour-suppressor genes. (10) For example, smoking 
status is positively associated with methylation of the promoter region of the fragile histidine 
triad (FHIT) gene and negatively associated with methylation of the promoter of the O6-
methylguanine-DNA methyltransferase (MGMT) gene. (3) 
 
Angiogenesis. VEGF levels in bronchial epithelial cells of smokers increase in association 
with the progression of bronchial dysplasia from low grade to high grade. Bronchial 
hyperplasia, metaplasia, and carcinoma in situ are associated with increased microvessel 
density, and a distinctive pattern known as angiogenic squamous dysplasia can occur. (11) 
Factors associated with increased tumor angiogenesis correlate with the development and 
prognosis of lung cancer. Circulating VEGF levels may predict the clinical benefit of VEGF 
inhibitors in patients with this disease. Many angiogenic factors are regulated at least in part  
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through the hypoxia-regulated pathways, such as hypoxia-induced factor (HIF) 1α and 2α. In 
addition to hypoxia, VEGF and other angiogenic factors are also regulated by EGFR through 
HIFdependent and independent mechanisms and by oncogenes such as KRAS and p53. (1) 
 
 
Figure 4. Two pathways to adenocarcinoma. Ligand binding to epidermal growth factor receptor (EGFR) induces 
homo- and hetero-dimerization of the receptor, resulting in activation of downstream effectors including the Ras–
MAPK (mitogen-activated protein kinase), PI3K (phosphatidylinositol 3-kinase)–Akt, and signal transducer and 
activator of transcription (STAT) pathways that lead to cell proliferation, survival and many other effects 
associated with carcinogenesis. The EGFR pathway is frequently activated in never smokers by mutations in the 
EGFR gene. In smokers, mutations of the KRAS gene often occur, resulting in the release of growth factors, 
including transforming growth factor-α (TGFα), which is a ligand for EGFR. In addition, Ras directly activates the 
PI3K–Akt pathway. Thus, the end result of KRAS or EGFR mutations are virtually identical,  and mutations of both 
genes in adenocarcinomas of the lung are rarely seen. Other methods of activation of these pathways include 
gene amplification and mutations in BRAF, PIK3CA (a subunit of PI3K), and ERBB2 (also known as HER2). (3) 
 
Technical advances: molecular profiling. Molecular profiling, including the profiling of genes 
and proteins, to guide treatment may improve the clinical outcome in patients with non–
small-cell lung cancer. Progress in the identification of markers, mutations, and genomic 
signatures far outstrips the modest improvement in treatments that are based on these 
molecular advances. Formidable obstacles to developing effective markers include tumor 
heterogeneity, the highly complex interplay between the environment and host and the 
complexity, multiplicity, and redundancy of tumor-cell signaling networks involving genetic,  
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epigenetic, and microenvironmental effects. Emerging high-throughput techniques for 
assessing genomic DNA, messenger RNA (mRNA), microRNA, methylation, and protein or 
phosphoprotein signaling networks should help address these obstacles. For the majority of 
patients with advanced or metastatic non–small-cell lung cancer, the most important potential 
effect of molecular markers is likely to be in predicting the response to specific therapies with 
the goal of “personalizing” treatment. Many exciting potential predictive markers have been 
developed in vitro and need validation in tumor samples and clinical trials. For example, 
gene-expression signatures have been developed for cisplatin and pemetrexed on the basis 
of in vitro sensitivity; the cisplatin in vitro signature predicted the likelihood of response. 
Recently developed in vitro profiles predicting the sensitivity of tumors to EGFR inhibitors 
and other therapies have yet to be assessed clinically. MicroRNA has recently emerged as 
an important regulator of gene expression. High-throughput analyses have shown that 
microRNA expression is commonly deregulated in lung and other cancers. Using real-time 
RT-PCR, investigators recently identified a five-microRNA signature that is associated with 
treatment outcome. Loss of microRNA-128b, a putative regulator of EGFR that is located on 
chromosome 3p, has been shown to correlate with the response to EGFR inhibition in 
patients with lung cancer. Studies suggest that information about tumor-specific genetic and 
epigenetic changes also may be obtained from the blood of patients with lung cancer. 
Circulating DNA can be detected in the plasma and serum of such patients, and levels of this 
DNA are associated with a poor prognosis. Tumor-specific DNA alterations (such as loss of 
heterozygosity), promoter methylation, and KRAS and EGFR mutations have also been 
detected in the blood of patients with lung cancer. New techniques for capturing circulating 
tumor cells allow the detection of EGFR-activating mutations and the drug-resistance allele 
T790M. Such techniques appear to be more sensitive than those for capturing circulating 
DNA. Furthermore, a decline in the number of circulating tumor cells was associated with 
tumor response on radiography. These studies suggest that blood profiling may provide 
useful information about genetic changes in tumors that could ultimately help detect lung 
cancer and guide therapy. 
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Profiling of genomic and mRNA expression provides an incomplete picture of the 
heterogeneity of non–small-cell lung cancer. Levels of mRNA do not always correlate with 
protein levels and do not provide information on protein–protein interactions or post-
translational modifications such as phosphorylation that may be critical for regulating protein 
activity. Furthermore, most targeted therapeutic agents are designed to inhibit the activity of 
proteins such as tyrosine kinases. Therefore, protein-based profiling is likely to be essential 
in understanding the complexity of protein signaling networks and developing molecular 
signatures that predict a response to therapy. Immunohistochemical analysis remains the 
most widely applied method for assessing individual proteins and may be useful for 
estimating prognosis and predicting the response to therapy. Emerging high-throughput 
proteomic techniques, such as mass spectrometry and protein microarrays, have the 
potential to view signal transduction networks more globally than is possible with 
immunohistochemical analysis. Such techniques are feasible in small amounts of tumor 
tissue. Proteomic signatures for prognosis and predicting the response to chemotherapy or 
EGFR inhibitors have been developed in tumors and cell lines. Proteomic profiling from blood 
is also under study, allowing repeated measurements during treatment without the need for 
tumor tissue. Serum mass spectrometry profiles can distinguish patients with non–small-cell 
lung cancer from normal controls and patients with better outcomes from those with worse 
outcomes after treatment with EGFR tyrosine kinase inhibitors. New techniques also permit 
the multiplex analysis of dozens of cytokines and angiogenic factors in small amounts of 
serum or plasma. This approach is being used in developing predictive markers in non–
small-cell lung cancer. Although promising, blood- and tissue-based proteomic approaches 
remain investigational and await prospective testing and validation in large, randomized trials 
before they can be applied clinically. (1) 
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Figure 5. Development of Personalized Drugs for Lung Cancer, from Identification of Genomic Signatures to 
Prospective Trials of Personalized Therapy. Host profiling involves innate characteristics of the cancer patient. All 
markers that are involved in profiling lung cancer can apply to the tumor or its local environment. Predictive 
markers identify groups of patients who are likely to have increased sensitivity or resistance to a given therapy, a 
critical step in personalizing treatment. It has been traditional to assess individual genetic or protein prognostic or 
predictive markers (e.g., HER2 for breast cancer), but emerging techniques permit global analyses of the 
genomic, gene-expression, epigenetic, and protein profiles of the host (innate), including markers in blood and in 
tumor or nonmalignant lung tissue. These methods include single-nucleotide polymorphism (SNP) arrays to 
assess genomic alterations, bisulfite sequencing, and methylation-specific polymerase chain reaction (PCR) to 
assess epigenetic changes, microarrays for assessing gene expression or microRNA levels, and proteomic 
methods (such as mass spectroscopy, reverse-phase protein arrays, and multiplex beads) to assess intracellular 
signaling in tumor tissue and cytokines and angiogenic factors in blood. Blood-based profiling includes markers 
derived from the host (e.g., lymphocytes) and the tumor and local environment (e.g., circulating tumor cells and 
tumor-derived cytokines) (red arrows). IHC denotes immunohistochemical analysis. (1) 
 
The molecular origins of lung cancer lie in complex interactions between the environment 
and host genetic susceptibility. Lung cancer then evolves through genetic and epigenetic 
changes, including deregulated signaling pathways, which are potential targets for 
chemoprevention and therapy. Emerging techniques for genomic, gene expression, 
epigenetic, and proteomic profiling could revolutionize clinical approaches across the 
spectrum of lung-cancer types and subtypes by identifying practical molecular markers of risk 
(in precancer), early detection and prognosis (in early-stage cancer), and treatment 
sensitivity (in early-stage and advanced stage cancer). Genomewide and other molecular  
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assessments are helping elucidate germ-line variations that may contribute to lung cancer 
risk, prognosis, and treatment sensitivity and somatic genetic alterations that occur in lung 
adenocarcinomas and in high-risk lung tissue associated with tumors or in smokers. (1) 
 
APOPTOSIS 
Apoptosis, or programmed cell death, is a normal component of the development and health 
of multicellular organisms. Cells die in response to a variety of stimuli and during apoptosis 
they do so in a controlled, regulated fashion. This makes apoptosis distinct from another form 
of cell death called necrosis in which uncontrolled cell death leads to lysis of cells, 
inflammatory responses and, potentially, to serious health problems. Apoptosis, by contrast, 
is a process in which cells play an active role in their own death (which is why apoptosis is 
often referred to as cell suicide). (12) Cells that undergo apoptosis are dismantled from 
within, in a controlled manner that minimizes damage and disruption to neighbouring cells. 
The resulting cellular debris is then removed, typically by professional phagocytes, and a 
new cell typically takes the place of the old one in a matter of hours. (13) 
 
 
Figure 6. Timeline of the most important steps in apoptosis research. (14) 
 
Morphological features. From the outside, it appears that cells that undergo this form of cell 
death initially become rounded and retract from neighbouring cells, which is reminiscent of 
what also happens when cells undergo mitosis. This is accompanied, or followed closely, by  
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a prolonged period of dynamic plasma membrane blebbing, which frequently culminates in 
the ‘pinching off’ of many of these blebs as small vesicles that have been named apoptotic 
bodies. Cells that undergo apoptosis are readily recognized as being different from their 
viable counterparts and are rapidly engulfed by phagocytes for recycling of their contents 
(1,2,5). This event is particularly remarkable when it is considered that phagocytes are 
normally engaged in the business of recognizing and removing foreign, or ‘non-self’, entities. 
However, in this instance, the dying cell becomes licensed for removal, despite having been 
a part of ‘self’ only minutes earlier. Indeed, for controlled cell elimination to operate, the 
minimum requirement seems to be for the chosen cell to undergo changes that attract the 
attentions of phagocytes. However, apoptotic cells also exhibit many other alterations to their 
internal architecture, which probably increase the efficiency of the disposal process and 
minimize activation of the immune system. 
Looking inside the cell, one of the most noticeable features of apoptosis is condensation of 
the nucleus and its fragmentation into smaller pieces (1,2,6), a highly distinctive event that is 
not seen under any other circumstances. Another defining characteristic of this mode of cell 
death is the extensive hydrolysis of nuclear DNA into numerous fragments, often down to 
multiples of 200 bp8. Although more subtle, the Golgi, endoplasmic reticulum (ER) and 
mitochondrial networks also undergo pronounced fragmentation during apoptosis, and 
numerous proteins are released from the mitochondrial intermembrane space (9,10). (13) 
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Figure 7. Morphology of apoptosis. a The morphology of apoptotic cells. HeLa cells were induced to die by 
exposure to daunorubicin (10 μM) for ~12 hours. The left panel shows cells after 2 h of exposure, when both cells 
in the field of view still appear healthy. By ~4.5 h (right panel), both cells display typical apoptotic morphology, 
with cell retraction and dynamic plasma membrane blebbing being evident. b Features of apoptosis-associated 
nuclear condensation and fragmentation. HeLa cells were induced to undergo apoptosis by treatment with 
actinomycin D (5 μM) followed by staining of nuclei (blue) with Hoechst dye. For comparison, a mixture of viable 
and apoptotic cells is shown. Apoptotic cells (arrows) exhibit extensive plasma membrane blebbing and contain 
nuclei that are condensed and/or fragmented into several pieces. C Fragmentation of mitochondrial networks. To 
visualize mitochondria, cells were transfected with a mitochondrially targeted green fluorescent protein construct, 
and then either left untreated (left panel) or treated with 5 μM actinomycin D for 12 h to induce apoptosis (right 
panel). Note that the mitochondrial network is extensively interconnected and appears filamentous in viable cells. 
By contrast, mitochondrial networks become highly fragmented in the early stages of apoptosis. (13) 
 
Molecular features. At the molecular level, all pathways to apoptosis converge on the 
activation of caspases, which are cysteinyl aspartate proteases that coordinate the efficient 
dismantling and engulfment of doomed cells. (15)  The caspases play an important role in 
apoptosis by activating DNases, inhibiting DNA repair enzymes and breaking down structural 
proteins in the nucleus.  
• Inactivation of enzymes involved in DNA repair. 
The enzyme poly (ADP-ribose) polymerase, or PARP, is an important DNA repair enzyme 
and was one of the first proteins identified as a substrate for caspases. The ability of PARP 
to repair DNA damage is prevented following cleavage of PARP by caspase-3.  
• Breakdown of structural nuclear proteins.  
Lamins are intra-nuclear proteins that maintain the shape of the nucleus and mediate 
interactions between chromatin and the nuclear membrane. Degradation of lamins by  
21 
caspase 6 results in the chromatin condensation and nuclear fragmentation. 
• Fragmentation of DNA.  
The fragmentation of DNA into nucleosomal units is caused by an enzyme known as CAD, or 
caspase activated DNase. Normally CAD exists as an inactive complex with ICAD (inhibitor 
of CAD). During apoptosis, ICAD is cleaved by caspases, such as caspase 3, to release 
CAD. Rapid fragmentation of the nuclear DNA follows. (12) 
Two pathways of cell death can be distinguished by whether they require BCL-2 family 
proteins and by which caspases are crucial for their execution.  
 
The intrinsic pathway. The intrinsic pathway — also called the BCL-2-regulated or 
mitochondrial pathway (in reference to the role these organelles play) — is activated by 
various developmental cues or cytotoxic insults, such as viral infection, DNA damage and 
growth-factor deprivation, and is strictly controlled by the BCL-2 family of proteins. This 
pathway predominantly leads to the activation of caspase-9 (Ref. 11) but, at least in certain 
cell types, the intrinsic pathway can proceed in the absence of caspase-9 or its activator, 
apoptotic protease-activating factor-1 (APAF1) (15). 
Mitochondria play an important role in the regulation of cell death. They contain many pro-
apoptotic proteins such as Apoptosis Inducing Factor (AIF), Smac/DIABLO and cytochrome 
C. These factors are released from the mitochondria following the formation of a pore in the 
mitochondrial membrane called the Permeability Transition pore, or PT pore. These pores 
are thought to form through the action of the pro-apoptotic members of the bcl-2 family of 
proteins, which in turn are activated by apoptotic signals such as cell stress, free radical 
damage or growth factor deprivation. Mitochondria also play an important role in amplifying 
the apoptotic signalling from the death receptors, with receptor recruited caspase 8 activating 
the pro-apoptotic bcl-2 protein, Bid. (12) 
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Figure 8. Illustration of the main apoptotic signalling pathways involving mitochondria (12) 
 
The bcl-2 proteins are a family of proteins involved in the response to apoptosis. Some of 
these proteins (such as bcl-2, bcl-XL, blc-W) are anti-apoptotic, while others (such as Bad, 
Bax or Bid) are pro-apoptotic. The sensitivity of cells to apoptotic stimuli can depend on the 
balance of pro- and anti-apoptotic bcl-2 proteins. When there is an excess of pro-apoptotic 
proteins the cells are more sensitive to apoptosis, when there is an excess of anti-apoptotic 
proteins the cells will tend to be more resistant. An excess of pro- apoptotic bcl-2 proteins at 
the surface of the mitochondria is thought to be important in the formation of the PT pore. 
The pro-apoptotic bcl-2 proteins are often found in the cytosol where they act as sensors of 
cellular damage or stress. Following cellular stress they relocate to the surface of the 
mitochondria where the anti-apoptotic proteins are located. This interaction between pro- and 
anti-apoptotic proteins disrupts the normal function of the anti-apoptotic bcl-2 proteins and 
can lead to the formation of pores in the mitochondria and the release of cytochrome C and 
other pro-apoptotic molecules from the intermembrane space. This in turn leads to the 
formation of the apoptosome and the activation of the caspase cascade. The release of 
cytochrome C from the mitochondria is a particularly important event in the induction of 
apoptosis. Once cytochrome C has been released into the cytosol it is able to interact with a  
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protein called Apaf-1. This leads to the recruitment of pro-caspase 9 into a multi-protein 
complex with cytochrome C and Apaf-1 called the apoptosome. Formation of the 
apoptosome leads to activation of caspase 9 and the induction of apoptosis. (12) 
 
The extrinsic pathway. Although there are differences in the signalling pathways activated by 
the different death receptors it is possible to outline a general apoptotic signalling pathway. 
Binding of the death inducing ligand to its receptor can lead to a the generation of ceramide, 
typically produced by acid sphingomyelinase. This ceramide release is thought to promote 
lipid raft fusion which results in a large scale clustering of the death receptors. The large 
scale receptor clustering is important because it helps to amplify the apoptotic signalling. In 
the absence of receptor clustering some cells, such as lymphocytes, are still able to trigger 
apoptosis but in most cases amplification of the signalling pathway is needed to activate the 
full apoptotic response.  
The extrinsic or death-receptor pathway is triggered by ligation of so-called death receptors 
(members of the tumour necrosis factor (TNF) receptor family, such as Fas, TNF receptor-1 
(TNFR1), TRAIL receptors DR4 and DR5), that contain an intracellular death domain, which 
can recruit and activate caspase-8 or -10 through the adaptor protein Fas-associated death 
domain (FADD; also known as MORT1) at the cell surface. This protein complex is often 
called the DISC, or Death Inducing Signalling Complex. This recruitment causes subsequent 
activation of downstream (effector) caspases such as caspase-3, -6 or -7, without any 
involvement of the BCL-2 family. In some cells, most notably hepatocytes, the extrinsic 
pathway can intersect the intrinsic pathway through caspase-8 cleavage-mediated activation 
of the pro-apoptotic BH3-only protein BID. The C-terminal truncated form of BID (tBID) 
translocates to mitochondria and promotes further caspase activation (caspase-9 and the 
effector caspases caspase-3, -6 and -7) through the intrinsic pathway. In these situations, 
loss of BID or overexpression of BCL-XL inhibits cell death. (12) 
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Figure 9. Illustration of the main TNF receptor signalling pathways. (12) 
 
TNF receptor signaling. TNF is produced by T-cells and activated macrophages in response 
to infection. By activating its receptor, TNFR1, TNF can have several effects. In some cells it 
leads to activation of NF-kB and AP-1 which leads to the induction of a wide range of genes. 
In some cells, however, TNF can also induce apoptosis, although receptor ligation is rarely 
enough on its own to initiate apoptosis as is the case with Fas ligand binding. Binding of TNF 
alpha to TNFR1 results in receptor trimerisation and clustering of intracellular death domains. 
This allows binding of an intracellular adapter molecule called TRADD (TNFR-associated 
death domain) via interactions between death domains. TRADD has the ability to recruit a 
number of different proteins to the activated receptor. Recruitment of TRAF2 (TNF-
associated factor 2) can lead to activation of NF-kB and the JNK pathway. TRADD can also 
associate with FADD, which leads to the induction of apoptosis via the recruitment and 
cleavage of pro-caspase 8. (12) 
 
Signaling by Fas (CD95). The ligand for Fas (FasL or CD95L) activated apoptosis in a similar  
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way to the TNF receptor. Binding of the ligand promotes receptor clustering, DISC formation  
and the activation of the caspase cascade. However, signalling through the Fas receptor is 
slightly simpler than through the TNF receptor. The adapter protein FADD can be recruited 
directly to the death domain on the Fas receptor, without requiring the prior recruitment of 
TRADD. In addition the Fas receptor is generally though to only activate apoptosis and does 
not play an important role in other aspects of cell signalling like the TNF receptor. 
 
Induction of apoptosis by TRAIL. In a number of ways TRAIL (TNF-related apoptosis 
inducing ligand) is similar in action to FasL. Binding of TRAIL to its receptors DR4 or DR5 
triggers rapid apoptosis in many cells. Interestingly there are also decoy receptors that 
compete for binding of TRAIL with the DR4 and DR5 receptors. The decoy receptors are 
called DcR1 and DcR2. Both of these receptors are capable of competing with DR4 or DR5 
receptors for binding to the ligand (TRAIL), however ligation of these receptors does not 
initiate apoptosis since DcR1 does not possess a cytoplasmic domain, while DcR2 has a 
truncated death domain lacking 4 out of 6 amino acids essential for recruiting adapter 
proteins. (12) 
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Figure 10. Scheme depicting intrinsic and extrinsic pathways of apoptosis. Apoptosis can be induced by cell 
surface receptors, such as Fas and tumour necrosis factor receptor-1 (TNFR1) (extrinsic pathway, right), or by 
various genotoxic agents, metabolic insults or transcriptional cues (intrinsic pathway, left). The intrinsic pathway 
starts with BH3-only protein induction or post-translational activation, which results in the inactivation of some 
BCL-2 family members. This relieves inhibition of BAX and BAK activation, which in turn promotes apoptosis. 
Some BH3-only proteins, such as BIM and PUMA, may also be able to activate BAX and/or BAK (as shown by 
the dotted line). Once activated, BAX and BAK promote cytochrome c release and mitochondrial fission, which 
leads to the activation of APAF1 into an apoptosome and activates caspase-9 to activate caspase-3. Caspases in 
turn cleave a series of substrates, activate DNases and orchestrate the demolition of the cell. The extrinsic 
pathway can bypass the mitochondrial step and activate caspase-8 directly, which leads to caspase-3 activation 
and cell demolition. The BCL-2 family regulates the intrinsic pathway and can modulate the extrinsic pathway 
when cleavage of BID communicates between the two pathways. (15) 
 
 
Apoptosis in health and disease. Apoptosis occurs during the normal development of 
multicellular organisms and continues throughout adult life. The combination of apoptosis 
and cell proliferation is responsible for shaping tissues and organs in developing embryos. 
For example the apoptosis of cells located in-between the toes allows for their separation.  
Apoptosis is also an important part of the regulation of the immune system. T lymphocytes 
are cells of the immune system that are responsible for destroying infected or damaged cells  
in the body. They mature in the thymus, but before they can enter the bloodstream they are  
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tested to ensure that they are effective against foreign antigens and are also not reactive 
against normal, healthy cells. Any ineffective or self-reactive T-cells are removed through the 
induction of apoptosis. 
Problems with the regulation of apoptosis have been implicated in a number of diseases. 
Cancer is a disease that is often characterized by too little apoptosis. Cancer cells typically 
possess a number of mutations that have allowed them to ignore normal cellular signals 
regulating their growth and become more proliferative than normal. Under normal 
circumstances damaged cells will undergo apoptosis, but in the case of cancer cells 
mutations may have occurred that prevent cells from undergoing apoptosis. In these cases 
there is no check on the cellular proliferation and consequently the disease can progress to 
the formation of tumors. In many cases these tumors can be difficult to kill as many cancer 
treatments rely on damaging the cells with radiation or chemicals and mutations in the 
apoptotic pathway often produce cells that are resistant to this type of attack. Understanding 
how apoptosis is regulated in cancer is therefore of major interest in the development of 
treatments for this disease. (12) 
Many mechanisms are involved in resistance to induced apoptosis in cancer. Indeed some 
tumor suppressor genes can be altered or oncogenes expression can be upregulated. p53 
was the first tumor suppressor gene linked to apoptosis. p53 mutations occur in the majority 
of human tumors and are often associated with advanced tumor stage and poor patient 
prognosis. In addition, several signal transduction pathways promote cell survival in response 
to growth and/or survival factors are upregulated in many tumors. One critical pathway 
involves signaling through PI-3 kinase, which can be activated by Ras and is downregulated 
by the PTEN tumor suppressor. Ras activation and PTEN loss are common in human 
tumors. 
The cloning and characterization of the bcl-2 oncogene established the importance of 
apoptosis in tumor development. bcl-2 was first identified at the chromosomal breakpoint of 
t(14;18) in a human leukemia line and was later shown to be a common event in follicular 
lymphoma. At this time, oncogenes were classified as either `transforming' or `immortalizing'  
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oncogenes based on their properties in rodent cell transformation assays. However, bcl-2 did 
not behave like a typical oncogene: instead of disrupting normal proliferation controls, Bcl-2 
promoted cell survival by blocking programmed cell death. In addition to Bcl-2, Bcl-xL is a 
potent death suppressor that is upregulated in some tumor types. Conversely, Bax is a death 
promoter that is inactivated in certain types of colon cancer and in hematopoietic 
malignancies. (16) Moreover, overexpression of molecules such as cFLIP or PED/PEA15 in 
many human cancer can confer resistance to apoptosis induced by TNF, FasL or TRAIL. 
If cancer is a disease where too little apoptosis occurs there are other diseases where too 
much apoptosis is thought to be part of the problem. For example in neurodegenerative 
diseases such as Parkinson’s or Alzheimer’s Diseases apoptosis is thought to account for 
much of the cell death and the progressive loss of neurons.  
Apoptosis is also important for normal placental development. During pregnancy trophoblast 
cells from the placenta invade the uterine environment in order to remodel the maternal 
blood vessels and help establish and maintain a successful pregnancy. Strict control over 
cell proliferation and apoptosis is required to achieve this. In some cases this process can be 
compromised and excessive apoptosis of the trophoblast cells is thought to be implicated in 
the failure to fully remodel the maternal environment that is observed in complications of 
pregnancy such as preeclampsia. 
Apoptosis is also thought to play a role in the progression of many auto-immune diseases. 
For example, in the case of rheumatoid arthritis excessive proliferation of synovial cells is 
thought to be due in part to the resistance of these cells to apoptotic stimuli. In other cases 
poor regulation of apoptosis in T-lymphocytes can result in auto-reactive T-cells entering the 
circulation and contributing to the onset of autoimmune diseases. (12) 
 
MIGRATION 
Cell migration is an essential process during, for instance, development and wound healing. 
Aberrations in signaling pathways involved in the regulation of cell migration, cell-cell and  
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cell-matrix interactions contribute to tumour invasion and metastasis. The regulation of 
cytoskeletal changes associated with migratory behaviour of cells has recently become 
focused on the family of small Rho-like GTPases. Cdc42, 
Rac1 and RhoA regulate signal transduction pathways that mediate distinct cytoskeletal 
rearrangements required for cellular motility. Besides these direct effects on the 
cytoskeleton, Rho-like proteins are involved in transcriptional activation, endo and exocytotic 
pathways, cell-cycle progression, oncogenic transformation and metastasis formation.  
Similar to Ras proteins, Rho-like GTPases function as molecular switches by cycling 
between an active GTP-bound state and an inactive GDP-bound state. The function of this 
switch is the regulated transmission of a signal perceived upon receptor stimulation of the 
cell to a downstream signaling pathway. This is achieved by the selective binding of the 
active GTPase to a downstream effector protein. Guanine nucleotide exchange factors 
(GEFs) stimulate the exchange of bound GDP for GTP leading to activation of the GTPases 
and binding of downstream effectors, thereby leading to transmission of the signal. GTPase-
activating proteins (GAPs) promote inactivation of the GTPases by stimulating the intrinsic 
GTP-hydrolysis rate of Rho-like proteins. Guanine nucleotide dissociation inhibitors (GDIs) 
can block the exchange of GDP for GTP as well as the hydrolysis of GTP, as has been 
shown for Rho GDI. GEFs are characterized by the catalytic Dbl-homology (DH) domain, 
which is C-terminally flanked by a Pleckstrin-homology (PH) domain. PH domains have been 
implicated in binding to specific phosphoinositol lipids, as well as to proteins. In addition to 
the DH-PH combination, many GEFs contain other domains (e.g. SH2-, SH3-, PDZ domains) 
that are commonly found in signalling molecules, allowing them to assemble in multi-
molecular signaling complexes. (17) 
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Figure 11. Basic Rho GTPase activation cycle. The loading of the Rho GTPases with GTP and subsequent 
activation is catalyzed by GEFs. In their GTP form they bind to different effectors to perform their functions. GAP 
proteins promotes the hydrolysis of GTP to inactivate the protein. RhoGDI proteins constitute an additional step of 
regulation by sequestering the protein in the cytoplasm impairing its function. Some examples of GEFs, GAPs 
and effectors are depicted. (18) 
 
 
Formation of intercellular contacts depends on the activity of Rho-like proteins. Recently, 
family members of the Rho-like GTPases have been recognized to be required for the 
maintenance of the cytoskeletal organization of fully differentiated epithelia. In human 
keratinocytes and Madin-Darby canine kidney cells (MDCK), dominant-negative N17Rac as 
well as C3 transferase, which inactivates RhoA by ADP-ribosylation on Asn41, have been 
found to perturb the organization of actin filaments at sites of cell-cell adhesion. Inactivation 
of Rac or Rho results in dislocation of E-cadherin and its complex members from the 
adherens junctions. The efficiency of dominant-negative mutants of Rho-like GTPases in 
perturbing the architecture of adherens junctions varies with respect to the maturation state 
of cell-cell contacts and to the cell type. Rho-like GTPases play a role in the structural 
integrity of adherens junctions. Inhibition of endogenous Rac and Rho function affects the 
architecture of adherens junctions and their marker protein E-cadherin, but has no effect on 
desmosome morphology (desmoplakin) in keratinocytes. Functional activity of the Rac and 
Rho protein is thus required for the integrity of both tight junctions and adherens junctions. 
Rac-dependent actin polymerization in lamellipodia and membrane ruffles has been shown 
to require PI3-kinase. Tiam1-mediated activation of Rac and the induction of cell-cell  
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adhesion in transformed MDCK cells is also dependent on PI3-kinase activity, suggesting 
that similar regulatory mechanisms participate in actin polymerization at cell-cell contacts and 
in the formation of lamellipodia required for cell migration. (17) 
 
Rho GTPases in cancer progression. Rho GTPases have been reported to contribute to 
most steps of cancer initiation and progression including the acquisition of unlimited 
proliferation potential, survival and evasion from apoptosis, tissue invasion and the 
establishment of metastases. Primary tumours generally arise as a consequence of multiple 
mutations and epigenetic changes affecting key genes that ultimately affect proliferation and 
survival. Activating mutations in the three Ras isoforms, Ki-Ras, N-Ras and Ha-Ras, are 
found in 15% of all human tumours. In contrast, Rho proteins are only rarely mutated in 
tumours, whereas their expression and/or activity are frequently altered. For example, 
several Rho GTPases are upregulated in some human tumours, including RhoA, RhoC, 
Rac1, Rac2, Rac3, Cdc42, Wrch2/RhoV and Rho. Uncontrolled proliferation, coupled to 
increased survival signals that permit tumour cells to escape from apoptosis, result in tumour 
growth. Some Rho GTPases stimulate cell cycle progression and regulate gene transcription, 
and this could in part explain their pro-oncogenic properties, for example in promoting Ras-
induced transformation. The induction of tumour vascularisation is essential for tumours to 
grow beyond a certain size and malignant cells release factors that promote angiogenesis 
from nearby pre-existing blood vessels. Some Rho GTPases are thought to be able to 
regulate the release of pro-angiogenic factors to promote neovascularisation. Invasion of 
epithelial cancers is initiated when the integrity of the epithelium is disrupted and malignant 
cells disrupt the basement membrane and enter the underlying stroma. This normally implies 
loosening of epithelial cell–cell contacts and acquisition of a more motile phenotype in a 
process frequently referred as epithelial to mesenchymal transition (EMT). Invasive epithelial 
cancer cells often have reduced expression of the cell–cell adhesion protein E-cadherin and 
start expressing markers of mesenchymal origin such as vimentin and N-cadherin. Non-
epithelial cancers also invade solid tissues. Degradation of the ECM by matrix  
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metalloproteases (MMPs) is essential for this kind of collective migration. To establish 
metastases in distant tissues, tumour cells have to enter the vascular or lymphatic system, 
then exit it and proliferate in the new tissue. The ability of Rho GTPase family members to 
regulate cytoskeletal dynamics, cell adhesion and cell migration points to a central role in 
cancer cell invasion and metastasis. (18) 
 
Rho subfamily. The Rho subfamily consists of the highly conserved RhoA, RhoB and RhoC 
proteins. RhoA and RhoC expression and/or activity is frequently increased in human 
tumours, whereas RhoB is often downregulated. RhoA has been implicated in virtually all 
stages of cancer progression. RhoA might play a role during tumour cell proliferation and 
survival: for example, in vitro, constitutively active RhoA can stimulate transformation. In 
normal epithelia, RhoA contributes to the generation of epithelial polarity and junction 
assembly and function but also affects epithelial disruption during tumour progression. Rho 
activity can be inhibited downstream of cadherins leading to a more motile phenotype. Rho 
GTPases can also regulate the production of MMPs, affecting matrix remodelling and tumour 
cell invasion.  
Increased RhoC expression has been claimed as the possible cause for the induction in 
invasion and metastasis and it can induce the production of angiogenic factors in breast 
cancer, and this could help promote entry into blood vessels and thereby metastasis. More 
extensive work is needed to elucidate the possible contribution of Rho GTPases to the 
extravasation of cancer cells. Unlike RhoA and RhoC, RhoB is often downregulated in 
human tumours and its expression inversely correlates with tumour aggressiveness. It has 
been proposed that RhoB can work as a tumour suppressor as it is activated in response to  
several stress stimuli including DNA damage or hypoxia, and it has been reported to inhibit 
tumour growth, cell migration and invasion and have proapoptotic functions in cells. (18) 
 
Cdc42 subfamily. Cdc42 and the closely related RhoQ/TC10 and RhoJ/TCL form a distinct 
subfamily of Rho GTPases. Cdc42 expression is upregulated in some breast cancers, yet 
liver-specific knock-out indicates that loss of Cdc42 enhances liver cancer development,  
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suggesting that the contribution of Cdc42 to cancer progression may be tissue-specific. This 
could reflect the multiple roles of Cdc42 in regulating cell polarity as well as cell cycle 
progression. Both Cdc42 and RhoQ/TC10 stimulate transformation and contribute to Ras-
induced transformation in vitro, and for Cdc42 this has been suggested to be due to its effect 
on receptor trafficking and degradation. RhoQ/TC10 is also implicated in receptor trafficking, 
particularly of the glucose transporter, but whether this accounts for its role in transformation 
is not known. Another mechanism whereby Cdc42 could affect cell cycle progression is by 
regulating chromosome segregation during mitosis: only Cdc42 knockdown out of all Rho 
GTPases was found to induce chromosome misalignment during cell division, leading to 
multinucleate cells. RhoJ/TCL and RhoQ/TC10 enhance this effect when suppressed in 
conjunction with Cdc42, pointing towards a possible redundancy in function of Cdc42 family 
proteins during spindle formation and cell division. Cdc42 is involved in the establishment of 
normal epithelial polarity as well as migratory polarity via its interaction with the 
Par3/Par6/aPKC polarity complex, which in turn regulates Rac via Tiam1. Cdc42 is thus 
predicted to inhibit invasion by promoting epithelial polarity, yet conversely also stimulate 
migration. Indeed, it contributes to cancer cell invasion in single cells in vitro with a 
mesenchymal morphology although probably not with an amoeboid morphology. It is also 
important for collective cancer cell invasion, where it acts through its target MRCK to 
stimulate actomyosin contractility. However, whether the Par3/Par6/aPKC complex is also 
involved in these processes is not yet known. (18) 
 
Rac subfamily. The Rac subfamily of Rho GTPases comprises Rac1, Rac2, Rac3 and RhoG. 
Rac1 is over-expressed in various tumours and accumulating evidence indicates that Rac1- 
dependent cell signalling is important for malignant transformation. Rac1 is one of the few 
Rho GTPases mutated in some tumours, with mutations mainly affecting the effector domain 
that interacts with downstream targets. It was proposed that these mutations could increase 
the activity of the protein and the survival of the tumours. A splice variant of Rac1, Rac1b, 
has an extra intron close to the GTP-binding region. It was initially identified to be 
upregulated in colon cancers. It does not bind RhoGDI and thus is present predominantly in  
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the GTP-bound state. Although Rac1b is defective in activating several Rac1-regulated 
signalling pathways, in some cell types it stimulates cell survival and cell cycle progression 
through NFjB, and is less susceptible to ubiquitination and degradation, which could explain 
its increased expression in cancers. So far little is known about the role of Rac proteins in 
cancer progression in vivo. Rac1 knock-out in mice is embryonic lethal but conditional knock-
out mice have been studied extensively. In a conditional lung cancer mouse model Rac1 
function was required for K-Ras-driven proliferation and tumorigenicity. Rac1 could contribute 
to cancer cell proliferation via regulation of the cell cycle: for example, it stimulates 
expression of cyclin D1, and induces cell transformation in vitro. It is likely to inhibit cancer 
invasion through its ability to enhance epithelial cell-cell adhesion. However, active Rac can 
mediate the loss of adherens junction in some situations, promoting a more migratory 
phenotype, and thus Rac could promote or inhibit tumour cell invasion depending on the cell 
background. Rac is necessary for the generation of lamellipodial protrusions during 
mesenchymal migration, as well as for the amoeboid migration of Ras-transformed cells. 
Rac1 can also contribute to cancer cell invasion by regulating the production of MMPs and 
their natural inhibitors, the Tissue-specific inhibitors of MMP (TIMPs). Like Rac1, Rac2 and 
Rac3 are over-expressed in some tumours. Rac3 is hyperactive and/or deregulated in breast 
cancers. The contribution of different Rac isoforms to migration is likely to depend on the cell 
type and their relative expression levels. Rac2 is required for neutrophil migration but 
whether it acts similarly in tumours is not known. In contrast, Rac1 and Rac2 are dispensable 
for cell migration in macrophages, although Rac1 is required for invasion. Studies of Rac3-
null mice indicate that Rac3 but not Rac1 or Rac2 specifically contributes to the development 
of Brc-Abl-induced lymphomas in vivo. However, in fibroblasts, Rac1 but not Rac3 
suppression by RNAi affects lamellipodium formation although cell invasion is reduced in 
both cases. It is not yet clear how these results can be translated to cancer cell invasion in 
vivo. Little is known about the role of RhoG in cancer, although it induces actin 
reorganization and cell migration via Rac in vitro, and thus it will be interesting to determine 
its role in cancer cell invasion. (18) 
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Regulation of cell motility by Rho-like GTPases: implications for invasion. Migrating cells 
extend lamellipodia and filopodia at the leading edge—structures which are regulated by Rac 
and Cdc42. Indeed, numerous studies have demonstrated that Rho-like proteins are 
important in cell migration. Since migration is a component of the invasive phenotype, it is 
perhaps not surprising that disruption of function of Rho-like GTPases also influences 
invasiveness in vitro. Increased Rac activity due to expression of the Rac exchange factor, 
Tiam1, or expression of constitutively active Rac, promotes migration and invasion of T-
lymphoma cells. However, expression of Tiam1 or active Rac actually inhibits the migration 
and invasion of epithelial cells. This is due to the ability of Rac to promote cadherin-mediated 
cell–cell adhesion, emphasizing the importance of the balance between cell–cell forces and 
migratory forces in determining the cellular response. In macrophages, migration is inhibited 
by both active and dominant negative mutants of Rac and Rho, suggesting that the right level 
of activity of Rho-like GTPases is critical. How Rac is involved in migration is not clear. One 
target of Rac is PIP 5-kinase, a phospholipid kinase which converts PIP to PIP2. PIP2 
induces the uncapping of actin filaments, leading to increased polymerisation. Increased 
actin polymerization in the advancing lamellipodia may be causal in promoting migration and 
invasion. Another target of Rac (and also Cdc42) is the serine/threonine kinase Pak (p21 
activated kinase). Active and inhibitory mutants of Pak can both stimulate and inhibit cell 
migration depending on the cell type and experimental conditions. The effects of Pak on 
motility and invasion may be due to effects on myosin-II light chain and/or heavy chain 
phosphorylation, which is enhanced by Pak. A model is emerging which suggests that Pak 
influences migration by promoting focal adhesion turnover, combined with stress fiber 
formation and contraction of the trailing edge. (19) 
 
Cell–matrix interactions and Rho-like GTPases. Integrin-mediated adhesion to the 
extracellular matrix plays an important role in the organization of tissues and the behaviour of 
individual cells. Transformed cells show changes in the profile of integrin expression that 
correlate with increased invasiveness. Increased invasiveness may be due to the effects of  
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changes in cell adhesion on cell motility. However, in addition to mediating adhesion, integrin 
engagement also modulates a number of intracellular signalling pathways that may also 
contribute to the invasive properties of cells. Rho-like GTPases have been implicated both as 
regulators of integrin-mediated cell adhesion and as downstream effectors of integrin 
signalling; they thus have the potential to regulate tumour invasion. One intermediate 
between integrin engagement and activation of Rho-like GTPases is phosphoinositide 3-
kinase (PI3K). PI3K is activated following integrin-mediated adhesion and its products 
promote activation of certain Rho-family exchange factors.  Consistent 
with these observations, integrin-mediated PI3K activation also promotes carcinoma 
invasion. Rho, Rac and Cdc42 can influence cell adhesion by driving the formation of 
integrin-containing focal complexes. These complexes also contain numerous signalling 
molecules including focal adhesion kinase (FAK) and paxillin and are therefore sites for 
intracellular signalling. The transient formation of these adhesion complexes combined with 
remodelling of the cytoskeleton may allow Rho-like GTPases to coordinate cell motility.  
Adhesion to the extracellular matrix can also regulate the activity of Rho like GTPases. 
Adhesion to fibronectin induces Cdc42 and Rac activation, whereas adhesion to laminin 
induces the activation of Rho. Adhesion also regulates the targetting of growth factor-
activated Rac to the plasma membrane and thus mediates the coupling of Rac with its 
downstream effectors. Indeed, a number of related proteins have been identified recently that 
form a complex with paxillin and Pak and may serve to target Rac to focal adhesions. The 
composition of the extracellular matrix and thus activation of specific integrins appears to 
determine the activation of Rho-like GTPases.  Specific integrin signals also determine the 
phenotypic responses to Tiam1–Rac signalling. Thus, Tiam1-induced Rac activation induces 
the migration of Ras-transformed MDCK cells plated on collagen, but restores a polarized 
epithelial phenotype on fibronectin or laminin. Interestingly, expression of β1 integrins 
actively disrupts adherens junctions in β1-deficient epithelial cells and promotes migration, 
whereas α5 integrins promote cadherin-mediated adhesion in myoblasts, leading to a  
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suppression of migration. Specific integrin signals may therefore regulate the localisation of 
Rho-protein signalling complexes (e.g. Tiam1–Rac) to sites of cell–cell or cell–matrix 
interaction and thus promote either intracellular adhesion or migration, respectively. (19) 
 
 
 
Figure 12. Rho-like proteins can influence both cell–cell adhesion and cell migration. Whether cells acquire an 
epithelial phenotype or an invasive mesenchymal-like phenotype depends on the balance between E cadherin 
mediated cell–cell contacts and pro-migratory forces. Tiam1/Rac signaling can promote either cell–cell adhesion 
or migration depending on the composition of the extracellular matrix, suggesting that integrin-mediated signalling 
may determine the localisation of Rho-protein signalling complexes, such as Tiam1/Rac. (19) 
 
Cell–cell adhesion forces modulate invasiveness. The integrity of epithelial monolayers is 
maintained by adherens junctions, which link the actin cytoskeletons of adjacent cells. 
Disruption of these junctions leads to the loss of cell–cell contacts and allows cell motility and 
invasion. Adherens junctions are specialised structures in the plasma membrane where E-
cadherin molecules from adjacent cells form homotypic associations. Cadherin–cadherin 
interactions are stabilised by the associated catenins (α-catenin, β-catenin and  γ-
catenin/plakoglobin), which link the cadherin molecules to the actin cytoskeleton. Indeed, 
adherens junctions are suppressed by mutations in the catenins, demonstrating the 
importance of this linkage with the actin cytoskeleton. In additionto stabilising existing 
adherens junctions, the actin cytoskeleton may play an active role in the formation of new 
cadherin-mediated cell–cell contacts by promoting the appositioning of adjacent cell 
membranes, allowing homotypic cadherin interactions to take place. Rho, Rac and Cdc42 
have all been reported to influence the integrity of adherens junctions—effects which are 
probably due to both modulation of adherens junction components and of the actin 
cytoskeleton. Rac (and Cdc42) may also modulate the stability of the adherens junction. (19) 
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The microtubule cytoskeleton and polarity. Although the effects of Rho GTPases on the actin 
cytoskeleton have received most attention to date, it is now clear that they can also modulate 
the microtubule cytoskeleton. While it is unlikely that the microtubule cytoskeleton plays an 
essential role during cell migration or chemotaxis over short distances, efficient and 
persistent long range migration requires stabilization of cell polarity and this is achieved 
through reorganization of the microtubule cytoskeleton. The first clue for a link between Rho 
GTPases and microtubules was the observation that nocodazole (an inhibitor that disrupts 
microtubules) activates Rho, but when washed out of cells it leads to Rac activation. Later, 
Rho was shown to promote the stabilization of microtubules through its target mDia that 
directly interacts with microtubules and promotes their capping. Rac, on the other hand, may 
promote microtubule elongation through p65PAKdependent phosphorylation and inactivation 
of the microtubule destabilizing protein, stathmin. The polarized migration of many cells is 
reflected in the reorganization of the microtubule cytoskeleton and the centrosome, which 
usually (though not always) face the direction of migration. This facilitates cell migration by 
directing transport pathways to the leading edge and is particularly important to achieve 
efficient and persistent migration over longer distances. Efficient cell migration requires 
integrin-dependent matrix adhesion to generate traction forces at the front and in the cell 
body, but integrin adhesion complexes must be dynamic and disassembled at the cell rear to 
allow the cell to pass. Members of the WASp/SCAR/WAVE family of scaffold proteins are 
key regulators of actin polymerization. In their activated state, each of these proteins is able 
to stimulate the Arp2/3 complex, which can initiate actin polymerization either de novo or at 
the barbed end or sides of preexisting filaments. In this way, the dendritic morphology of 
lamellipodial actin is generated. WASp/WAVE can also bind to profilin, which acts 
synergistically with Arp2/3 to speedup actin polymerization. Cdc42 activates WASp and N-
WASp directly, although the lipid PI(4,5)P2 is an essential cofactor. Rac activates the 
Scar/WAVE family indirectly and this involves an Nck-adaptor complex. (20)   
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 Figure 13. A migrating cell (seen from the top and side). A migrating cell needs to perform a coordinated series of 
steps to move. Cdc42 regulates the direction of migration, Rac induces membrane protrusion at the front of the 
cell through stimulation of actin polymerization and integrin adhesion complexes, and Rho promotes actin:myosin 
contraction in the cell body and at the rear. (20) 
 
MAPK and cellular migration structures. The mitogen-activated protein kinase (MAPK) 
pathways that activate ERK, JNK and p38 kinases play important roles in modifying the 
morphogenetic and motile responses of cells. These pathways receive inputs from both 
soluble growth factors and extracellular matrix proteins to regulate the localization, amplitude 
and duration of MAPK signaling, and hence the spectrum of targets phosphorylated. 
Emerging data implicate MAP kinase signaling in the control of F-actin and focal adhesion 
formation and turnover required for cell morphogenesis and migration. Binding of growth 
factors to cognate receptor tyrosine kinases at the plasma membrane promotes activation of 
Ras. Ras recruits Raf family kinases to the membrane where they are activated by 
incompletely understood mechanisms including phosphorylation/dephosphorylation and lipid 
binding. Active Raf phosphorylates and activates the dual specificity tyrosine and threonine 
kinases MEK1&2, which are upstream kinases for ERK1&2. Activated ERK can be  
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translocated to the nucleus to regulate transcription or retained/routed within the cytoplasm 
to regulate diverse activities including cell motility, organelle structure, integrin signaling and 
cytoskeletal dynamics.  
ERK is also implicated in the co-ordinate control of Rho and Rac activities in fibroblast 
models of transformation and human tumor cells. However, the precise mechanisms and 
targets through which ERK signals, and their spatiotemporal control, are not well understood. 
In these situations, ERK signaling does not acutely influence Rho function, but rather 
sustained ERK signaling selects for down-regulation of Rho or 
Rho effector function.  
The presence of activated MEK and ERK on cytoskeletal structures and their association 
with focal adhesions and microtubules is consistent with the hypothesis that localized MAPK 
signaling modulates Rho signaling. Indeed, considerable evidence indicates that the 
integration of Rho family GTPase and ERK signaling is important in the control of cell 
morphogenesis. Integrin activation of MAPK requires c-Src and FAK, and ERK activity is 
required for FAK stimulated focal adhesion disassembly to promote cell migration. Several 
studies have shown that FAK or v-Src can suppress the activities of Rho and its effector, 
ROCK, and this pathway requires ERK signaling to modulate actin and focal adhesion 
dynamics. (21) 
 
PED/PEA15 
PED, (phosphoprotein enriched in diabetes), also known as PEA15, (phosphoprotein 
enriched in astrocytes), is 15 kDa adaptor protein involved in many cellular pathways, among 
which are apoptosis, autophagy, survival, proliferation and migration (22-24). It was first 
identified as a phosphoprotein highly expressed in astrocytes and then found overexpressed 
in type II diabetic patients. PEA-15 exists in vivo as three isoforms, namely N, Pa and Pb, 
which correspond to the unphosphorylated, mono and diphosphate forms, respectively. 
Phosphorylation occurs on two seryl residues. The first one, Ser104, is located within the 
motif LTRIPSAKK, is a PKC target. The second site, Ser116, is included in the motif  
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DIRQPSEEEIIK, and is the target of the CaMKII and AKT. Membrane-permeant 
phosphatase antagonists were therefore used to determine the PEA-15 dephosphorylation 
pathway: okadaic acid (OK) that inhibits phosphatase 2A (PP2A) and, with a lesser efficacy, 
phosphatase 1 (PP1), Calyculin A (CalA) which is equipotent to inhibit PP1 and PP2A, and 
Tautomycin (Tau) that preferentially inhibits PP1. PEA-15 phosphorylation was rapidly 
enhanced following treatment of the striatal astrocytes with OKand CalA whereas Tau was 
poorly effective. These results suggest that PP2A is essentially involved in PEA-15 
dephosphorylation. (23)  
 
The ped gene and its transcriptional regulation. Two forms of mouse PED cDNA that differ in 
the length of the 3’UTR have been cloned. These likely represent transcripts generated by 
alternative polyadenylation. Northern blots indicate that expression of PED is predominant in 
the CNS. However, ped transcripts are also detected in several peripheral organs. This 
suggests additional functions for PED required in multiple cells and tissues, beside its 
specific role in astrocytes. The ped gene has now been cloned in several mammals and 
found to be highly conserved.  Furthermore, computer analysis of the drosophila genome did 
not reveal any sequence related to ped. Thus, it might be possible that ped only appeared 
with mammals. The genomic sequence of pea15 is composed of four exons and spans 
approximately 10.2 kb of genomic DNA flanked upstream by a potentially expressed Alu 
element and downstream by the H326 gene. The human ped gene was mapped to 1q21–
q22, between the markers D1S2635 and D1S484. A few diseases were mapped to this 
region, including type II diabetes in Pima Indians, autosomal dominant non-syndromic 
hearing impairement locus, DNFA7, hyperparathyroidism-jaw syndrom, familial hemiplegic 
migrane, MHP2, a non-Hodgkin lymphoma and the loop–tail mutation in mouse. A detailed 
gene scan didn’t found any evidence for a ped mutation in type II diabetes or loop–tail 
mutation. In addition to the remarkable conservation of the PED protein sequence, three 
highly conserved regions are found within the 3’UTR of its cDNAs, each greater than 100 
nucleotides in length. 3’UTRs are known to contain regulatory sequences that signal mRNA  
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localization, translational regulation and direct degradation. Conserved sequences found in 
mouse and human PED cDNA 3’UTR are good candidates for such roles. Indeed, several 
infrequent regulatory motifs were found in these regions, including JCV repeats. The human 
JC polyomavirus (JCV) is the etiologic agent of the neurodegenerative disease progressive 
multiple leukoencephalopathy, and replicates only in astrocytes.  In good agreement with an 
important function of PED 3’UTR, is the presence within this region of the protooncogene 
MAT1. Indeed, it was demonstrated that MAT1  cDNA is a partial sequence of the PED 2.4 
kb mRNA does not encode a protein. TheMAT1 sequence was isolated from a mouse 
mammary tumor induced in vitro with N-methyl-N-nitrosourea and lithium, and was reported 
to induce the oncogenic transformation of NIH- 3T3 cells. Accordingly, increased expression 
of PED transcripts was reported in numerous tumors, including gliomas, the main primary 
tumors of the brain. (23) 
The molecular mechanisms that regulate PED expression in human cancer are still unclear. 
Recent studies revealed that PED expression can be regulated by several transcription 
factors. Hepatocyte nuclear factor 4 alpha (HNF-4α), which is involved in induction of 
apoptosis in pancreatic INS-1 beta-cell line, negatively regulates PED expression (25), while 
its expression is upregulated by Chicken Ovalbumin Upstream Promoter-Transcription Factor 
II (COUP-TFII) (25), by vitamin D receptor (VDR) upon vitamin D3 treatment (26) and by IL-4 
(interleukin-4) (27).  More recently we demonstrated that PED levels may be regulated by 
microRNAs (Incoronato et al., personal communication, Cancer Research, submitted). 
 
PED role in apoptosis. Membrane receptor-induced apoptosis results from an orderly 
cascade of cellular events. Upon binding to their respective ligands, Fas and TNFR1 
receptors, FasL or TNF initiate apoptosis by recruiting the cytosolic adaptor molecule FADD 
to the plasma membrane to form a multiprotein complex named death inducing signaling 
complex (DISC). The N-terminal part of FADD contains a DED that binds to homologous 
domains located in the N-terminal part of caspase-8 allowing the activation of the caspase. 
Mutants of FADD lacking DED, or mutants of caspase-8 with only its DEDs can act as  
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dominant-negative inhibitors suggesting that endogenous inhibitors of the early steps of 
apoptosis could exist. (23) PED is member of Death Effector Domain (DED) containing 
protein family. These domains were described to regulate cell death through protein-protein 
interaction (24).  
 
 
 
Figure 14. Apoptosis related molecole homology. 
 
In particular, PED was described to inhibit DISC (Death Inducing Signaling Complex) 
formation and caspase 8 activation upon death cytokines stimulation (FasL, TNFα, TRAIL) in 
different cell types (22-24). PED molecules in the proximity of caspase-8 and caspase-10 in 
the DISC may prevent further cleavage of the caspases according to the induced proximity 
model. Indeed, PED can be recruited in the DISC. PED expression is required to divert 
astrocytes from the deleterious effects of TNF. This was demonstrated using astrocytes from 
wild type versus PED null mutant mice. Astrocytes lacking PED and exposed to TNF rapidly 
exhibited the classical signs of apoptosis including inversions of membrane lipids, evidenced 
by annexin V labeling, and nuclear fragmentation leading to the formation of DNA ladders. 
Re-expression of PEA-15 after transfection restored protection and survival. (23) 
Furthermore, Hao et al. found increased PED expression in primary human malignant glioma 
cell lines. (28) We recently demonstrated that PED expression is altered in B-CLL (B-cell 
chronic lymphocytic leukemia) (29) and non-small cell lung cancer (NSCLC) (30), where it 
mediates resistance to  TRAIL (TNF-Related Apoptosis Inducing Ligand) induced apoptosis. 
Interestingly, PED needs to be double in its diphosphate form to be recuited to the DISC. 
Moreover, PED can contribute to apoptosis resistance to chemotherapies for breast cancer 
(31).  
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Figure 15. Extrinsic pathway inhibition by PED.  Inhibition of caspase-8 and -10 cleavage and activation mediated 
by PED when it is recruited to the DISC.  
 
PED affects MAPK signaling: effects on proliferation and migration. PED is particularly 
enriched in mature, non-dividing astrocytes. During development of the brain, PEA-15 
expression begins relatively late at embryonic day 12 (E12) and reach the adult levels by 
postnatal day 10 (P10) when cell proliferation is strongly reduced in the CNS. Moreover, the 
levels of PED in proliferating astrocytes are lower than in non-proliferating astrocytes in 
cultures. Conversely, PED null mice exhibit a marked increase in cell proliferation in several 
lineages including astrocytes, lymphocytes and hepatocyte. 
Thus, PED expression appears closely, and inversely, correlated with cell proliferation. The 
ERK1/2 p44/42 ERK MAP kinase cascade seems essential for entry into the cell cycle 
Multiple substrates of ERK1 and ERK2 have been characterized, located in different 
subcellular compartments such as the plasma membrane for the epidermal growth factor 
receptor, the cytosol for the microtubule destabilizing protein stathmin, or the nucleus for the 
transcription factor Elk1. The inactive ERK is essentially located in the cytosol. Its activation 
leads to its translocation into the nucleus, an event that seems to be essential for ERK action 
and signal termination. The first evidence for a link between PED and the MAP kinase 
signaling pathway came from the reversal of the H-Ras inhibition of integrin signaling by PED  
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expression, evidenced using expression cloning. Surprisingly, PED blocked Ras effect on 
integrin without affecting its stimulation of ERK activity. It was subsequently demonstrated a 
direct interaction between PEA- 15 and the MAP kinase cascade after a yeast two-hybrid 
screen, using PED as a bait, that allowed to characterized ERK1 and ERK2 as the PED 
partners. PED is not a substrate for ERK. Indeed, PED lacks the canonical proline-directed 
ERK phosphorylation sites and is not phosphorylated by ERK in vitro. PED alters the output 
of ERK signaling without blocking ERK activation. Indeed, we observed that PED does not 
interfere with ERK activation or activity. PED does not affect the phosphorylation of ERK 
cytosolic substrates, such as stathmin or p90RSK, but it blocks the phosphorylation of ERK 
nuclear substrates, such as Elk-1, with a consequent inhibition of ERK-dependent 
transcription. PED modifies ERK signaling by excluding ERK from the nucleus. PED contains 
a nuclear export signal (NES) that is required for ERK localization to the cytosol. (23) 
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Figure 16. PEA-15 regulates both TNFalpha-induced apoptosis and ERK-dependent transcription. (A) PEA-15 
participates in the formation of the DISC formed of the receptor, FADD, caspase-8 as mentioned in the text, 
where it may bind to FADD and/or pro-caspase-8, blocking the activation of the caspase. An indirect effect on 
ERK (dotted line) may also participate in the anti-apoptotic effect of PEA-15. (B) PEA-15 binds and exports ERK 
from the nucleus, redirecting the kinase activity toward its cytosolic substrates. (23) 
 
Additional functions of PED. Using differential display to identify genes whose expressions 
are altered in tissues derived from type II diabetes mellitus patients compared with 
nondiabetic individuals, Condorelli et al. cloned cDNAs encoding PED, which they named 
PED for ‘‘phosphoprotein enriched in diabetes’’. They found that PED mRNA was 
overexpressed in fibroblasts, skeletal muscle, and adipose tissue from type II diabetics. The 
protein levels were also elevated in type II diabetic tissues. Furthermore, transfection of a 
PED cDNA into differentiating L6 skeletal muscle cells increased the content of glucose 
transporter-1 (GLUT1) on the plasma membrane and inhibited insulin-stimulated glucose 
transport and cell surface recruitment of glucose transporter-4 (GLUT4). These effects were 
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reversed by the inhibition of PKC activity, suggesting that the phosphorylation of PED might 
be involved. While the role of ERK in glucose transport is uncertain, based on our data it is 
reasonable to predict that PED overexpression could block glucose stimulated ERK 
translocation. This may partly explain the changes observed in glucose transport and cell 
surface recruitment of GLUT4 in type II diabetes. A two-hybrid search also evidenced an 
interaction of PED with PLD1, that was further confirmed in intact cells. Elevated levels of 
PLD1 activity were observed in vitro and in vivo after co-expression with PED. This 
enhanced PLD1 activity was correlated with elevated levels of PLD protein, leading to the 
conclusion that PED was affecting the accumulation or degradation rates of PLD1 rather than 
its activity per se. (23) 
 
Tandem Affinity Purification (TAP) 
The sequencing of complete genomes of several organisms provides an exceptional 
opportunity to analyze the all different functions governed by their genes. Insights into these 
complex biological systems can be gained by the analysis of gene regulatory networks and 
by determining the identity, modification, and expression levels of encoded protein as well as 
by defining interactions existing among proteins (proteomic analyses). Large-scale two-
hybrid screening has been used for this latter purpose. However, false-positive and false-
negative results, the lack of information about stoichiometry, and the limited set of conditions 
testable make it desirable identification vary from protein to protein, making it impossible to 
able to use additional strategies to easily detect interactions. Biochemical purification of 
proteins in combination with mass spectrometry allows identification of interacting partners.  
The Tandem Affinity Purification (TAP) method is a purification procedure based on a fusion 
of a tag to the target protein and the final recovery of the target protein and its interacting 
partner through mass spectrometry analysis.  
The TAP method involves the fusion of the TAP tag to the target protein and the introduction 
of construct into the host cell or organism. For optimal results, it is preferable to maintain 
expression of the the fusion protein at, or close to, its natural level. Indeed, overexpression of  
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the protein often induces its association with nonnatural partners (heat shock proteins, 
proteasome). Cell extracts are prepared and fusion protein as well as associated partners is 
recovered by two specific affinity purification/elution steps. The material recovered can be 
analyzed in several ways. For protein complex characterization, proteins are concentrated, 
and eventually fractionated on a denaturing  gel before identification by mass spectrometry. 
Because the various TAP purification steps are performed in a gentle native manner, purified 
complexes may also be tested for their activities or used in structural analysis.  
The TAP tag consists of two IgG binding domains of Staphylococcus aureus protein A 
(ProtA) and a calmodulin binding peptide (CBP) separated by a TEV protease cleavage site. 
Both affinity tags have been selected for highly is efficient recovery of proteins present at low 
concentration. ProtA binds tightly to an IgG matrix, requiring the use of the TEV protease to 
elute material under native conditions (Fig. 1B). The eluate of this first purification step is 
then incubated with calmodulin coated beads in the presence of calcium. After washing, 
which removes contaminants and the TEV protease after the first affinity selection, the bound 
material is released under mild conditions with EGTA conditions have been developed for the 
generic use of the TAP strategy. The TAP-tag is, however, very tolerant to buffer conditions 
changes and can easily be implemented to optimize recovery of specific complexes. (32) 
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Figure 17. Schematic representation of the subtraction strategy. (40) 
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Methods (I) 
Materials. Media, sera and antibiotics for cell culture were from Life Technologies, Inc. 
(Grand Island, NY, USA). Protein electrophoresis reagents were from Bio-Rad (Richmond, 
VA, USA), and Western blotting and ECL reagents were from Amersham (Aringhton Heights, 
IL, USA). All other chemicals were from Sigma (St. Louis, MO, USA) unless otherwise stated. 
The following primary antibodies were used: anti-PED antibody (33); anti-β-actin antibody 
(Ab-1, mouse IgM, Oncogene, Darmstadt, Germany); anti-caspase 8 antibody (1C12) Cell 
Signaling Technology, Inc. (Danvers, MA, USA), anti-caspase 3 antibody (Abcam, 
Cambridge, USA); anti-caspase 10 antibody (StressGene, Victoria, BC Canada); anti-cFLIP 
(NF6) antibody (Alexis, Lausen, Switzerland); anti- FADD antibody (BD Transduction 
Laboratories, San Jose, CA, USA); anti-TRAIL receptor antibodies (R&D Systems, 
Minneapolis, MN, USA); anti PARP antibody (SC7150) (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). 
 
Cell culture. Human CALU-1 and A459 NSCLC cell lines were grown in DMEM; H460 and 
A549 cell lines were grown in RPMI. Media were supplemented with 10% heat-inactivated 
FBS, 2mM L-glutamine and 100U/ml penicillin-streptomycin. 
 
Protein isolation and Western blotting. Lung tissue specimens (neoplastic and adjacent 
normal tissue) were collected during surgical intervention on 27 patients affected with lung 
tumor, in accordance with the ethical standards of the institutional responsible committee on 
human experimentation. The clinical and pathological characterization (including TNM 
staging) of these patients, which were not receiving medical treatment at the time of the 
operation, is shown in Table 1. The collected samples were homogenized in 1ml PBS (0.14M 
NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4) containing 1% Triton X-100 and 
Proteinase Inhibitor Cocktail, with a tissue homogenator. Cultured cells were pelleted, 
washed twice with cold PBS and lysed in the same harvest buffer. Solubilized proteins were 
incubated for 30 min on ice, and after centrifugation at 10,000 g for 30 min at 4°C,  
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supernatants were collected. Fifty μg of sample extract were resolved on 12% SDS-
polyacrylamide gels using a mini-gel apparatus and transferred to Hybond-C extra 
nitrocellulose. Membranes were blocked for 1 h with 5% non-fat dry milk in TBS containing 
0.05% Tween-20, incubated for 2 h with primary antibody, washed and incubated with 
secondary antibody, and visualized by chemiluminescence. 
 
Cell death and cell proliferation quantification. Cells were plated in 96-well plates in triplicate 
and incubated at 37°C in a 5%CO2 incubator. To induce apoptosis, Superkiller TRAIL (Alexis 
Biochemicals, Lausen, Switzerland) was used for 24 h at 10ng/ml. Cell viability was 
evaluated with the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA), according to the manufacturer’s protocol. Metabolically active cells were 
detected by adding 20 μl of MTS to each well. After 2 h of incubation, the plates were 
analyzed in a Multilabel Counter (Bio-Rad, Richmond, VA, USA). Apoptosis was also 
assessed using annexin V–FITC Apoptosis Detection Kits followed by flow cytometric 
analysis. Cells were seeded at 1.8 106 cells per 100-mm dish, grown overnight in 10% 
FBS/RPMI, washed with PBS, then treated for 24 hours with 200 ng/ml TRAIL. Following 
incubation, cells were washed with cold PBS and removed from the plates by very mild 
trypsinization conditions (0.01 % trypsin/EDTA). The resuspended cells were washed with 
cold PBS and stained with FITC-conjugated annexin V antibody and propidium iodide (PI) 
according to the instructions provided by the manufacturer (Roche Applied Science, 
Indianapolis, IN). Cells (50,000 per sample) were then subjected to flow cytometric analysis. 
Propidium iodide staining and flow cytometry analysis were done as described [19]. 
 
Flow cytometry. The relative level of surface TRAIL receptors was assessed by FACS 
analysis. To this end, 1 million cells were collected and washed twice in PBS, incubated with 
PE-conjugated purified monoclonal antibodies against TRAIL receptors or with mouse 
isotype control phycoerythrin IgG2b for 1 hour on ice, and then washed once with 3 ml PBS. 
After centrifugation, the cell pellet was resuspended in 1 ml PBS and analyzed with a  
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FACSsort (Becton Dickinson, Franklin Lakes, NJ, USA). 
 
Small interfering (si) RNAs. The Dharmacon siDesign Center software program was used to 
design a duplex siRNA targeting PED mRNA (siPED). This duplex consisted of a 21 nt 
doublestranded RNA, comprised of 19 base pairs with two T, 3’ overhanging ends, 
synthesized by Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA) 
(UCACUAUGGUGGUUGACUATT). c-FLIP siRNA was purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA) (sc-35388). siCONTROL Non-Targeting siRNA 
Pool #2 (D-001206-14-05) was from Dhamarcon (Lafayette, CO, USA) and comprised four 
siCONTROL Non-Targeting siRNAs. Each individual siRNA within this pool was 
characterized by genome-wide microarray analysis and found to have minimal offtarget 
signatures. 
 
Transfection experiments. CALU-1 or H460 cells were cultured to 80% confluence in p60 
plates. 100 nM of control, PED or c-FLIP siRNA were transiently transfected in cells kept in 
antibiotic-free, serum-containing medium, using LIPOFECTAMINE 2000, according to the 
manufacturer’s instructions. Cells were incubated with siRNAs for the indicated times. PED 
protein levels were upregulated where indicated by transfecting cells with 5 μg of pcDNA3-
Myc PED. 
 
Tissue microarray (TMA) construction and immunohistochemistry (IHC). 0.6 mm-diameter 
cylinders were punched from donor blocks in areas identified as neoplastic after analysis of 
hematoxylin/eosin (H&E) stained sections. The tissue cylinders were inserted into a recipient 
paraffin block using a precision instrument (Beecher Instruments, Sun Prairie, WI, USA). 
Standard indirect staining procedures were used for IHC (ABC-Elite-Kit, Vector Laboratories, 
Burlingame, CA, USA). After heat-induced pre-treatment (in citrate buffer, pH6, water bath at 
90° for 30 min) for antigen retrieval, a rabbit polyclonal anti-PED antibody  was applied for 2 
h at adilution of 1:5000 at 37°C. The slides were then incubated with the secondary,  
53 
biotinylated antibody. Osmium-enhanced diaminobenzidine was used as the chromogen. 
Counterstaining was carried out with Harris’ hematoxylin. Only fresh cut sections were 
stained to minimize the influence of slide ageing and maximize repeatability and 
reproducibility of the experiment. For negative controls, the primary antibody was omitted; as 
positive control, normal tissue with known PED positivity was used. For each sample, 
percentage of positive tumor cells and staining intensity (0,faint, moderate or intense) were 
recorded. A case was graded: a) negative, if no cells were stained; b) weakly positive (mild), 
if up to 33% of cells were stained; c) moderately positive if 34-66% of cells were stained; or 
d) strongly positive if 67% 100% of cells were positive. Staining intensity was not used for 
correlation with clinical findings, as it can vary depending on the manner of tissue fixation. 
The slides were all evaluated in one day by one experienced pathologist (DB). 
 
Methods (II) 
Cell culture, treatments. The human neuronal stem cell line (HNSC.100) was propagated in 
DMEM:F-12 (1:1) medium, supplemented with 0.5% FCS (Life Technologies, Inc. Grand 
Island, NY, USA), 1% N2 (Life Technologies, Inc., Grand Island, NY, USA), 1% BSA 
(Sigma), 1% Penicilin/Steptomycine and human recombinant growth factors EGF and FGF-α 
(Tebu Biochem, 20nM each). For differentiation, the mitogens were removed and replaced 
with CNTF (100nM) for about 2 weeks. Differentiated HNSC.100 were treated for 24h with 
ethanol vehicle, or 10-7M vitamin D3 (Biomol, CA) and lysates were prepared with ice-cold 
lysis buffer (20mM MOPS, pH 7.2, 2mM EGTA, 3.5mM EDTA, 30mM sodium fluoride, 60mM 
glycerophosphate pH 7.2, 20mM sodium pyrophosphate, 1mM sodium orthovanadate, 1mM 
phenylmethylsulfonylfluoride, 3mM benzamidine, 5μM pepstatin A, 10μM leupeptin, 1% 
Triton X-100). 
Real-time PCR. Total RNA was extracted from A549 cells using the TRIZOL reagent protocol 
(InVitrogen). Quality and quantity of the RNA were determined by measuring the absorbance 
at 260 and 280 nm, and by 1% agarose gel electrophoresis under denaturing conditions. 
RNA (1μg) from each sample was reverse transcribed and one-step RT-PCR was performed  
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by using SuperScript® III First-Strand system (Invitrogen) according to manufacturer’s 
instructions. Primers for PEA-15 were: 5’-GCAGTGCCTGGTTTAGCTTC-3’ (forward), 5’-
TACGGGTTAGCTTGGTGTCC-3’ (reverse) and were synthesized commercially (PRIMM, 
Milan, Italy). Real-time PCR was performed by using iQTM SYBR® Green Supermix (BIO-
RAD). Reactions were performed in triplicate and β-Actin used as an internal reference 
cycling (conditions are available upon request). 
 
Methods (III) 
Plasmids. Expression vectors for Rac wild type, RacQL, Rac12V and Vav1 were kindly 
provided by Dr. Mario Chiariello. PED-MYC expression plasmid was previously described 
(33). PED-MYC S104G was realized through AGT-GGT single nucleotide substitution 
(QuikChange Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA, USA). ShRNAi-PED 
and shRNAi-scrambled were from Open Biosystems (Huntsville, AL, USA), GST-CRIB has 
been previously described (34). 
 
Tandem Affinity Purification. A459 cells were lysed in TEB buffer (50 mM Tris-HCl, pH 8, 150 
mM NaCl, 5% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 2 mM EGTA and protease inhibitors 
from Roche) for 2 h under gently mix and cleared by centrifugation for 30 min at 13000 rpm. 
The lysate was incubated with rabbit-IgG agarose beads (Sigma, St. Louis, MO, USA) 
overnight at 4°C. Beads were collected by centrifugation (3000 rpm for 5 min), and then 
extensively washed firstly with TEB buffer and then with TEV-protease cleavage buffer (TCB: 
10 mM Tris-HCl (pH 8), 150 mM NaCl and 0.1% Triton X-100, 0.5 mM EGTA). Beads were 
then incubated with 150 μl TEV protease in 1.5 mL of TCB overnight at 4°C. The TEV-
protease cleavage products were colleted and then loaded onto calmodulin sepharose beads 
(GE Healthcare, Piscataway, NJ, USA) in Calmodulin Binding Buffer (CBB: 10 mM Tris-HCl, 
pH 8, 150 mM NaCl, 0.1% Triton X-100, 1 mM MgAcetate, 1mM Imidazole, 2 mM CaCl2) 
supplemented with 250 mM CaCl2 at 4°C for 1.5 h. Beads were recovered by centrifugation 
at 3000 rpm for 5 min and then extensively washed with CBB. Proteins retained on the beads  
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were eluted by incubation with Calmodulin Eluition Buffer (CEB:10 mM Tris-HCl, pH 8, 150 
mM NaCl and 0.1% Triton X-100, 1 mM MgAcetate, 1 mM Imidazole) with three different 
CaCl2 concentrations (2, 10 and 20 mM). The eluate was collected and concentrated by 
methanol/chloroform precipitation before loading onto a 12% SDS– PAGE. 
 
Mass spectrometry analysis and protein identification. The gel was stained with colloidal 
Coomassie blue (Sigma, St. Louis, MO, USA). Protein bands were excised from the gel, 
reduced, alkylated and digested with trypsin (35). Peptide mixtures were extracted from the 
gel and analyzed by nano-chromatography tandem mass spectrometry (nanoLC–MS/MS) on 
a CHIP MS Ion Trap XCT Ultra equipped with a capillary 1100 HPLC system and a chip cube 
(Agilent Technologies, Palo Alto, CA, USA). Peptide analysis was performed using data-
dependent acquisition of one MS scan (mass range from 400 to 2000 m/z) followed by 
MS/MS scans of the three most abundant ions in each MS scan. Raw data from nanoLC–
MS/MS analyses were employed to query a non-redundant protein database using in house 
MASCOT software (Matrix Science, Boston, MA, USA). 
 
Virus production. We produced vector stocks by calcium phosphate transient transfection, 
cotransfecting three plasmids in 293 T human embryonic kidney cells, since these cells are 
good DNA recipients. The three plasmid are: the packaging plasmid, pCMVDR8.74 designed 
to provide the HIV proteins needed to produce the virus particle; the envelope-coding 
plasmid, pMD.G, for pseudotyping the virion with VSV-G and TWEEN PED-TAP vector, the 
transgene coding plasmid. The calcium phosphate–DNA precipitate was allowed to stay on 
the cells for 14–16 h, after which the medium was replaced, collected 48 h later, centrifuged 
at 1000 rpm for 5 min at room temperature and filtered through 0.22 mm pore nitrocellulose 
filters. 
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Generation of lentiviral vectors and gene transfer. For PED-TAP plasmid, we PCR-amplified 
PED cDNA from PED-MYC expressing vector and subcloned into the pBS1761 plasmid for 
TAP-tagging of proteins at the N-terminus. For TWEEN PED-TAP vector, we PCR-amplified 
PED-TAP cDNA from PED-TAP expressing vector and subcloned into the lentiviral vector 
TWEEN17 under control of them cytomegalovirus promoter. On the day of infection, the 
medium was removed and replaced with viral supernatant to which 4 mg/ml of Polybrene had 
been added. Cells were then centrifuged in their plate for 45 min in a Beckman GS-6KR 
centrifuge, at 1800 rpm and 32°C. After centrifugation, cells were kept for either 1 h 15 min or 
ON in a 5% CO2 incubator at 32 or 37°C, respectively. After exposure, cells were washed 
twice with cold PBS and fresh medium added. At either 12 or 48 h after the infection, cells 
were washed with PBS, harvested with trypsin/EDTA and analyzed by FACS for GFP 
expression. 
 
Cell culture. Human A459, A459 TWEEN, A459 TWEEN PED-TAP and HeLa cell lines were 
grown in DMEM containing 10% heat-inactivated FBS and with 2 mM L-glutamine and 100 
U/ml penicillin-streptomycin. PEDshRNA A459 clones (#1 and #2) and SCRAMBLEDshRNA 
A459 clone were grown in DMEM medium containing 10% heat-inactivated FBS, with 2 mM 
L-glutamine and 100 U/ml penicillin-streptomycin and selected with 2.5 µg/ml puromycin from 
Sigma (St. Louis, MO, USA). 
 
Western blotting. Total proteins from A459 and HeLa cells were extracted with RIPA buffer 
(0.15 mM NaCl, 0.05 mM Tris-HCl, pH 7.5, 1% Triton, 0.1% SDS, 0.1% sodium deoxycolate 
and 1% Nonidet P40). Fifty µg of sample extract were resolved on 10 –15% SDS-
polyacrylamide gels using a mini-gel apparatus (Bio-Rad Laboratories, Richmond, CA, USA) 
and transferred to Hybond-C extra nitrocellulose. Membranes were blocked for 1 hr with 5% 
non-fat dry milk in TBS containing 0.05% Tween-20, incubated over night with primary 
antibody, washed and incubated with secondary antibody, and visualized by 
chemiluminescence. The following primary antibodies were used: anti- PAP (Peroxidase- 
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Anti-Peroxidase Soluble Complex), anti-β-Actin antibodies from Sigma (St. Louis, MO, USA), 
anti- Rac1 antibody from Abcam (Cambridge, MA, USA); anti- phospho ser71 Rac1, anti- 
phospho ser104 PED, anti- ERK 1/2, anti- phospho ERK 1/2, anti- ELK1, anti- phospho-
ELK1, anti- MYC-tag antibodies from Cell Signalling (Danvers, MA, USA), anti- phospho 
ser116 PED antibody from Biosource International Inc. (Camarillo, CA, USA), anti- PED 
antibody (33), anti- AU5, anti- HA antibodies from Covance (Emeryville, CA, USA). 
 
Immunoprecipitation. Cells were cultured at a final concentration of 90% in p100 plates. The 
cells were harvested with RIPA Buffer on a shaker for 30 minutes. 1 mg of total extract was 
immunoprecipitated using the indicated antibodies (4 µg/ml Anti-Rac1, 4 µg/ml Anti-PED), for 
16 hrs on shaker. Then, A/G beads (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
were added for two hrs. The beads were washed for three times with washing buffer (50 mM 
Tris Hcl pH 7.5, 150 mM NaCl, 0.1% Triton, 10% glycerol), and then 20 µl of sample buffer 
was added; the samples were boiled at 100°C for 5 minutes and then the supernatants 
resolved by SDS-PAGE. 
 
siRNA and plasmid transfection. A459 cells were cultured to 80% confluence and transiently 
transfected using LIPOFECTAMINE 2000 (Invitrogen, Carlsbad, CA, USA) with 150 nM anti-
PED siRNAs and anti-Rac1 siRNAs (Dharmacon, Lafayette, CO, USA), or with control 
vector, PED, PED S104G, Rac, RacQL, Rac12V, Vav1 cDNAs as reported in the paper, as 
described in the manufacturer's protocol. 
 
Rac1 pull-down assay. Plates were starved for 24 h and then treated as indicated. After a 
quick wash with iced-cold PBS, cells were lysed with GST-Fish buffer (50 mM Tris/HCl ph 
7.4, 2 mM MgCl2, 1% NP-40, 10% glycerol, 100 mM NaCl, 1 µg/ml leupeptin, 1 µg/ml 
pepstatin, 1 µg/ml aprotinin, 1 mM PMSF and 2 mM DTT). After 10 min at 4°C under  
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agitation, cells were scraped and lysates were cleared by centrifugation in a precooled rotor. 
150 µg of total protein extract was mixed with 10 µg of GST-PAK-CRIB domain coupled to 
glutathione-sepharose beads and incubated 30 min at 4°C under agitation. Beads were the 
rinsed three times rapidly with 1 ml of iced-cold GST-Fish buffer. The amounts of total Rac 
and Rac-GTP were estimated by immunoblot against Rac1. 
 
Migration assay. Transwell Permeable Supports, 6.5 mm diameter inserts, 8.0 µM pore size, 
polycarbonate membrane (Corning Incorporate, Corning, NY, USA) were used to perform 
migration assay. A459 and HeLa cells were grown as indicated above, then harvested by 
TrypLETM Express (Invitrogen, Carlsbad, CA, USA) and 105 cells were washed three times 
and then resuspended in 1% FBS containing DMEM medium and seeded in the upper 
chamber. Lower chamber of the tranwell was filled with 600 µl of culture medium containing 
10% FBS, 5 µg/ml fibronectin, as an adhesive substrate. Cells were incubated at 37°C for 24 
h. Transwell were then removed from 24-well plates and stained with 0.1% Crystal Violet in 
25% methanol. Nonmigrated cells were scraped off on the top of the transwell with a cotton 
swab. % of migrated cells was evaluated by eluiting crystal violet with 1% SDS and reading 
the absorbance at λ 570 nm.  
 
Invasion assay. A similar procedure as in migration assay was used. The upper chamber of 
the transwell was filled with 100 µl of BD MatrigelTM (BD Biosciences, San Jose, CA, USA). 
BD MatrigelTM was diluited to 1mg/ml in serum free culture medium and put into the top of the 
traswell. Then it was incubated for 4 h for gelling. Cells were counted and treated as 
indicated above. Invaded cells were measured as % over control cells, transfected with 
empty vector. 
 
Wound healing. Cells were cultured as confluent monolayers, synchronized in 1% FBS for 24  
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h, and wounded by pipette tip. Wounded monolayers were washed twice with PBS to remove 
nonadherent cells. Wound healing was followed up to 24 hours. For these studies, cells were 
seeded in 35 mm Petri dishes and kept at 37°C in a humidified atmosphere with 5% CO2.  
 
Results (I) 
PED expression in NSCLC tissue. Specimens were collected from 27 NSCLC-affected 
patients (clinical features are summarized in Table 1) and processed for Western blotting. 
PED was increased in the tumor tissue of all the patients analyzed and only rarely expressed 
in the adjacent normal tissue (Figure 18a). The mean PED expression level was six-fold 
higher in the transformed areas compared to normal tissue (Figure 18b). Furthermore, 
analysis of TNM staging revealed that the expression of PED was greater during the initial 
stages of the disease (T1 and N0) than in T2 and N1 lesions (Figure 18c). We also analyzed 
PED expression on a TMA constructed from 160 different histological lung cancer samples. 
As shown in Table 2, PED expression was considered high in the majority of cases and in all 
the types of lung tumor present, with only 4% of the tumors analyzed resulting negative for 
PED staining. Immunohistochemical analysis of PED expression is depicted in Figure 19 
where it is possible to evaluate the different PED staining intensity. Panel A represents an 
example of PED negative staining; panel B, of mild, panel C of moderate and panel D of 
strong PED staining. The majority of samples showed strong staining for PED. 
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Table 1. Age (years), sex and TNM (tumor, node, metastasis) staging [30] of patients (P) are reported. All 
patients were smokers. Histology of the tumors indicated that most were adenocarcinoma (ADENO) and the 
remaining squamous cell carcinomas (SQUAM). 
 
 
 
Table 2: PED expression analyzed in the lung cancer TMA. Top number indicates number of cases present in the 
TMA; the bottom number indicates its relative percentage. PED expression was graded: negative: no staining; 
mild: 0-33% positively staining cells; moderate: 34-66% positively staining cells; Strong: 67-100% positively 
staining cells. 
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Figure 18. PED expression is increased in human lung cancer. (a) Western blots showing expression of PED in 
tumor (T) and adjacent normal (N) lung tissue from some of the 27 NSCLCaffected patients (Pt). β-Actin was 
used for the loading control. (b) Graph of densitometric analysis. Mean ± SD PED expression of all the tumor 
samples (T) normalized to β-actin and expressed as % respect to the adjacent normal tissue (N). PED was >6-
fold higher in cancer tissue compared to normal areas. (c) PED expression during T1, T2, T3 and N0, N1 and N2 
stages of the disease. PED expression is greater during the initial stages (T1 and N0) of the disease compared 
with the T2 and N1 lesions. 
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Figure 19. PED expression levels in NSCLC cancer samples. Immunohistochemical analysis of paraffin-
embedded NSCLC sections labeled with anti-PED antibody (1:5000) and revealed by secondary, biotinylated 
antibody. (a) negative (b) mild; (c) moderate; (d) strong staining. 
 
PED expression correlates with resistance to TRAIL in NSCLC cell lines. PED is a DED-
containing protein that inhibits the formation of a functional DISC following treatment with 
different apoptotic stimuli, including TRAIL, in several cell types. We therefore, investigated 
whether PED expression correlated with resistance to TRAIL in different NSCLC cell lines. 
As shown in Figure 20a, PED is expressed at higher levels in CALU-1 cells compared to 
H460 cells. Intermediate levels of expression were observed in A459 and A549 cells. When 
exposed to TRAIL, H460 cells underwent TRAIL-induced cell death, whereas CALU-1 cells 
were completely resistant (Figure 20b and c). A459 and A549 cells exhibited intermediate 
sensitivities to TRAIL (Figure 20b and c). Therefore, PED expression levels correlated with 
TRAIL resistance in the NSCLC cell lines 
analyzed. We also studied several components of the extrinsic cell death signaling pathway. 
As shown in Figure 20a, the expression of these TRAIL signaling molecules was comparable 
in the four cell lines, although c-FLIP expression was slightly lower in H460 cells. 
 
TRAIL resistance in NSCLC cells does not depend on the expression of TRAIL receptors. 
TRAIL resistance could be correlated with different expression levels of TRAIL receptors. In  
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order to exclude this possibility, we investigated the cell surface expression of all four TRAIL 
receptor subtypes in NSCLC cells. As shown in Figure 21, expression of functional and 
decoy TRAIL receptors was comparable in all cell lines. 
 
Figure 20. PED expression correlates with TRAIL resistance in NSCLC cell lines. (a) Fifty μg of total cell extract 
from CALU-1, H460, A459 and A549 cells were analyzed by Western blotting for the expression of PED and other 
TRAIL signaling molecules. β-actin was used as the loading control. Representative blots are shown. (b) Viability 
after treatment with TRAIL. Cells were incubated with superKiller-TRAIL (10 ng/ml) for 24 hrs and viability 
evaluated as described in the methods section. Mean ± SD of three independent experiments in triplicate. (c) 
Annexin V and propidium iodide (PI) staining of NSCLC cells after TRAIL treatment. Mean ± SD of four 
independent experiments in duplicate. 
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Figure 21. Surface expression of TRAIL receptors does not differ in TRAIL-resistant and TRAIL-sensitive cells. 
Surface expression of the four TRAIL receptor isotopes (R1, R2, R3 and R4) was analyzed by flow cytometry with 
specific PE-conjugated antibodies. Isotype-matched antibodies were used as control for unspecific binding. 
Receptor expression levels were comparable in CALU-1 and H460 cells. 
 
Effect of the down regulation of PED and c-FLIP on insensitivity to TRAIL in CALU-1 cells. To 
better clarify the role of PED in TRAIL resistance in lung cancer cells, we transfected CALU-1 
cells with PED siRNA. PED siRNA specificity was tested in CALU-1 cells by the co-
transfection of PED siRNA with Myc-tagged PED cDNA. The PED siRNA duplex suppressed 
both endogenous (15 kDa) and exogenous (20 kDa) PED expression, while a control siRNA 
was not effective in reducing PED protein levels (Figure 22a). This silencing effect was 
evident at 48 hrs and more marked at 72 hrs. We found that also other in cell lines (HeLa, 
Human embryonic kidney 293) PED siRNA was able to knock down PED expression (data 
not shown). Transfected cells were then exposed to TRAIL. As expected, siRNA-mediated 
knock-down of PED was responsible for sensitization of CALU-1 cells to TRAIL-induced cell 
death (Figure 22b). Interestingly, comparable results were obtained when we knocked-down 
PED expression in A459 and A549 cells (Figure 22b). The treatment of CALU-1 cells with a 
specific c-FLIPL siRNA down-regulated c-FLIPL expression but did not increase sensitivity to  
 65 
TRAIL-induced cell death (Figure 22c). These data further confirm that PED protects lung 
cancer cells from TRAIL-induced apoptosis, and that inhibiting PED expression results in 
increased TRAIL sensitivity. 
 
Figure 22. Down regulation of PED restores TRAIL sensitivity in CALU-1 cells. (a) PED siRNA or a control oligo 
were transiently transfected in CALU-1 cells in the presence or absence of PEDMyc cDNA. Cells were incubated 
for 48 or 72 hrs and analyzed by Western blotting. The PED siRNA duplex suppressed both exogenous and 
endogenous PED expression, whereas control siRNA had no effects. (b) PED siRNA effects in A459 and A549 
cells. PEDsi RNA, transfected in NSCLC cells was able to reduce PED expression levels (right panel) and induce 
an increase in TRAIL sensitivity (left panel), as assessed by flow cytometry. Mean ± SD of two independent 
experiments in duplicate. (c) c-FLIPL siRNA or PED siRNA were transfected as described in Methods. Cells were 
analyzed for c-FLIP expression after 72 hrs incubation. c-FLIPL siRNA but not PED siRNA was able to reduce c-
FLIPL expression Effects of silencing PED and c-FLIPL on TRAIL-induced cell death: CALU-1 cells were 
transfected with siRNA for PED, c-FLIPL or control for 48 hrs, after which cells were trypsinized, plated in 96-well 
plates in triplicate and further incubated with superKiller-TRAIL for 24 hrs. Metabolically active cells were then 
detected asindicated in the Methods. Mean ± SD of four independent experiments in duplicate. Downregulation of 
PED, but not cFLIPL, was responsible for increased sensitivity of CALU-1 cells to TRAIL-mediated cell death. 
 
Effects of silencing PED on caspase activation in CALU-1 cells. We then examined the 
activation of caspase 8 and PARP upon exposure to TRAIL in CALU-1 cells treated with PED 
siRNA. As shown in Figure 23a, TRAIL-induced caspase 8 and PARP activation was greater 
in CALU-1 cells following PED siRNA transfection. 
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Effect of increasing PED expression on TRAIL sensitivity in H460 cell. In order to further 
evaluate the role of PED in apoptosis resistance, TRAIL-sensitive H460 cells were 
transfected with PED cDNA to up-regulate PED protein levels and then analyzed for their 
susceptibility to TRAIL-induced cell death. Increasing the expression of PED in these cells 
(Figure 23c) rendered them resistant to TRAIL, as assessed by Western blotting for caspase 
8 and PARP (Figure 23b) or by a cell viability assay (Figure 23d). 
 
 
Figure 23.  Effects of PED on caspase activation. (a) CALU-1 cells were transfected with PED or  control siRNA 
for 72 hrs and then treated with superkiller TRAIL for the indicated times. Lysates were examined by Western 
blotting with anti-caspase 8 or anti PARP antibodies. Cleavage of caspase 8 and PARP was detected at a greater 
amount in CALU-1 cells transfected with PED siRNA. β-actin was used as the loading control. (b) PED cDNA 
(PED-Myc) was transiently transfected in H460 cells and cells were analyzed for caspase 8 and PARP activation 
as previously described or for or for cell viability (d) as indicated. (c) Western blot analysis of PED expression 
revealed that transfection increased PED expression levels in H460 cells. β-actin was used as the loading control. 
Representative blots are shown. 
 
These results were published on  J Cell Mol Med. 2008 Dec;12(6A):2416-26. Epub 2008 Feb 
15 
 
In collaboration with the group of Theo Rein, Max Planck Institute of Psychiatry, Munich,  
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Germany, we analyzed PED transcriptional regulation. This study aimed to investigate 
targets of vitamin D3 in a human brain stem cell line. We employed arrays with antibodies 
directed against more than 600 structural and signalling proteins including phospho-variants. 
Over 180 proteins responded to vitamin D3, such as cyclin-dependent protein-serine kinase 
1/2, epidermal growth factor receptor-tyrosine kinase, protein kinase A, protein-serine kinase 
Bγ and proteinserine kinase Cα. PED resulted strongly up-regulated. In silico promoter 
analysis revealed conserved binding sites for vitamin D3 receptor, suggesting a strong 
vitamin D3 dependency of the PEA-15 promoter. The results shown here are those made in 
our laboratory. 
 
Results (II) 
We chose the human neuronal stem cell line HNSC.100 as a model. This cell line is derived 
from a 10-10.5 weeks gestational age human Caucasian embryo and has been immortalised 
by stable v-myc expression. These cells can be differentiated and up-regulate markers of 
three lineages (astrocytes ≥85%, neurons 10 -15% and oligodendrocytes ≤1%;).  We 
employed antibody microarrays to detect proteins that were changed in their expression or 
modification/activation upon treatment with vitamin D in our cellular model. Several structural 
and signalling proteins were identified. These targets were tested for reproducibility by 
Western-blot analysis using an independent set of HNSC.100 protein extracts. Several 
candidate proteins were confirmed, with a particularly strong effect (up-regulation) for PED. 
 
PED promoter analysis and mRNA induction by vitamin D3. Given the strong response of 
PED to vitamin D3 indicated by two independent samples/methods and its prominent 
expression in the CNS (particularly abundant in astrocytes), we focused our further 
experiments on this candidate. First, we searched by bioinformatics tools for VDR binding 
sites in the PED promoter of the human, mouse and rat genomes. The sequence upstream  
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of the transcription site contains several transcription factor binding motifs, including those for 
NFκB, EGRF, EKLF and SP1 (Figure 24a). One of these sites is conserved between human, 
mouse and rat promoter, thus strongly indicating a functional vitamin D3 – dependency of the 
PED gene promoter. To experimentally test the up-regulation of the PED gene promoter by 
vitamin D3 we treated cells with vitamin D3 and measured the mRNA of PED by real time 
PCR. We observed indeed a rise of the PED mRNA already after 3h and 6h (Fig. 24b). Using 
an antibody that recognises PED irrespective of its phosphorylation status we also detected 
an up-regulation of the total amount of PEA protein after 12h (Figure 24c). 
 
 
Figure 24. Conserved transcription factor binding sites in the promoter of PED and up-regulation of PED mRNA 
and protein. A. Several transcription factor binding motifs were identified, including those for VDR, NFκB, EGRF, 
EKLF and SP1. B. Effect of vitamin D3 on PEA15/PED mRNAlevels. A549 cells were treated with vitamin D3 (10-
7M) and the mRNA levels were determined by real time PCR at the times indicated. C. Verification of induction of 
total PED after 12h by Western blot. 
 
Vitamin D3 regulates PED function. We investigated whether the effect of vitamin D3 on PED   
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expression changes cellular processes that depend on the function of PED.  Numerous 
studies suggest the involvement of PED in a broad range of antiapoptotic processes in 
cultured cells. TRAIL (tumor necrosis factor apoptosis-inducing ligand) is an efficient inducer 
of apoptosis and in TRAIL-sensitive cells; transfection of PED cDNA resulted in cell 
resistance, whereas inhibition of PED expression changed the TRAIL-resistant phenotype to 
sensitive. Given that normal astrocytes are generally TRAIL-resistant, we chose the TRAIL-
sensitive cell line A549 to examine VDR and PED expression in the presence and absence 
of vitamin D3. First, we verified by Western blot that A549 cells express VDR (not shown). To 
test whether vitamin D3 influences TRAIL-induced apoptosis, we pre-treated A549 cells with 
vitamin D3 (10-7M) for 12h before apoptosis was induced with TRAIL (100 ng/ml for the next 
24h). Cell nuclei were visualized with propidium iodide and subjected to FACS analysis to 
monitor late stage apoptosis and MTS proliferation assays were performed to measure cell 
viability. Treatment with vitamin D3 alone did not have a significant effect on apoptosis, as 
compared to vehicle-treated cells, whereas treatment with TRAIL resulted in 50% apoptotic 
cells, as expected. Notably, cells pre-treated with vitamin D3 prior to TRAIL administration 
exhibited markedly decreased levels of TRAIL-induced apoptosis. MTS assays paralleled the 
observed changes, indicating that a decrease in cell proliferation/viability induced by TRAIL 
could be significantly reverted by pre-treating cells with vitamin D3. To answer the crucial 
question of whether the effect of vitamin D3 is dependent on PED, we silenced the PED gene 
with siPEA RNA, prior to treating cells with vitamin D3 and TRAIL (reduced PED expression 
level are documented below the graphs of Figure 25b). Interestingly, the attenuating effect of 
vitamin D3 on the actions of TRAIL in apoptosis and cell viability was completely abolished in 
PEA15 silenced cells (Figure 25b, dark grey bars). These data suggest that PED is 
mediating the effects of vitamin D3 in cell survival.   
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Figure 25. Effect of vitamin D3 on TRAIL-induced apoptosis and cell survival in A549 cells. A. Cells were treated 
with vehicle, vitamin D3 and TRAIL in the combinations indicated. Metabolic activity (as a measure of cell viability 
and apoptosis (FACS analysis) were determined. B. Same treatment as in A, but in the presence of RNAi directed 
against PEA15/PED. Data represent mean values + SEM of three independent experiments performed in 
triplicates each. Panel below B, verification of the efficacy of the siRNA directed against PED by Western blot 
using an antibody detecting total PED. 
Vitamin D3 increases phosphorylation of AKT1 and PED. The strong up-regulation observed 
using an antibody directed against PED phosphorylated at serine 116 raised the question of 
whether the increase in the level of total protein is achieved in part by increasing protein 
stability. It has been reported that PED is phosphorylated by protein kinase B/AKT1 which 
leads to stabilisation of the protein. Therefore, we used Western blot analysis to measure the 
levels of phosphorylated AKT1, total AKT1, phosphorylated PED, and total PED after 
treatment of the cells with vitamin D3. Phosphorylation of AKT1 is a measure of the activity of 
this kinase. We observed an activation of AKT1 3h and 6h after addition of vitamin D3, while 
the level of total AKT1 protein was unchanged (Figure 26). Interestingly, 6h after addition of 
vitamin D3 we found an increase in phosphorylation of PED, but no change in the level of 
total PED yet (Figure 26), which rises only after 12h (Figure 24). This data supports the view 
that vitamin D3 uses two mechanisms to increase the function of PED, stimulation of gene  
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transcription and stabilisation of the protein through phosphorylation, possibly via activation  
of AKT1.  
 
Figure 26. Effect of vitamin D3 on AKT and PED. A549 cells were treated with vitamin D3, and harvested at the 
times indicated. Western analysis was performed to detect the levels of total AKT (AKT), phosphorylated AKT 
(pAKT), total PEA15/PED, phosphorylated PED (pPEA15), and α-actin.as loading control. 
These results were published on J Cell Mol Med. 2009 Mar 27. [Epub ahead of print] 
To better understand PED role in cancer, we focused on PED interactome characterization in 
Non Small Cell Lung Cancer (NSCLC) cell line A459. By the Tandem Affinity Purification 
(TAP), we identified Rac1, member of mammalian Rho GTPase proteins family, as PED-
interacting protein. a member of mammalian Rho GTPase proteins family which switches 
between an active GTP-bound state and an inactive GDP-bound state. Rac1 binds to a 
variety of effector proteins thus regulating a wide range of cellular effects such as secretory 
processes, phagocytosis of apoptotic cells, epithelial cell polarization, growth factor-induced 
formation of membrane ruffles, ROS generation, lamellipodia formation and cell migration.  
 
Results (III) 
PED interacts with Rac1. Tandem Affinity Purification was used in order to discover new 
PED interactor. A459 cells were infected with tween-PED-TAP construct or with tween empty 
vector as control. The total protein lysate was incubated with immunoglobulin derivatised 
agarose beads and the retained sample eluted by hydrolysis with TEV protease. PED 
containing complexes were finally purified onto Calmodulin derivatised beads. After these 
72  
two purification steps, the sample and the control were fractionated by SDS-PAGE, the entire 
lanes from the gel were cut in slices and each gel slice was submitted to the identification 
procedure (fig. 27A and 27B). The resulting peptide mixtures were directly analyzed by mass 
spectrometry (LC-MS/MS) and identified by MASCOT protein database search. Common 
proteins identified in both the control and the sample lanes were discarded and only those 
proteins solely identified in the sample and absent in the control were selected as putative 
PED interactors. Several new candidate proteins were identified and among these we 
focused our attention on Rac1, because of its involvement in cancer signaling pathways. 
PED and Rac1 interaction was also confirmed by immunoprecipitation experiments from 
A459-tween PED-TAP cells (fig. 27C), from A459 transfected with Rac1 (fig. 27D) and from 
wild type A459 cells (fig. 27E). PED and Rac1 co-immunoprecipitation was evident either 
with exogenous or with endogenous proteins. 
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Figure 27. PED interacts with Rac1. (A) Samples from Tandem Affinity Purification collected at each step of the 
protocol. Lanes: (1) 40 µg of total extract; (2) 40 µg of supernatant after IgG incubation; (3) TEV cleavage control; 
(4) IgG beads after TEV cleveage; (5) supernatant after Calmodulin beads; (6) Calmodulin beads before final 
eluition; (7,8,9) eluition with 2, 10 and 20 mM EGTA. (B) Comassie staining of preparative polyacrilammide gel. 
Our PED-CBP bait is indicated at 23 KDa. A459 cells infected with TWEEN vector were used as negative control. 
(C) Co-immunoprecipitation of endogenous Rac1 with exogenous PED-TAP. 1 mg of total extract  
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immunoprecipitated using an anti-Rac1 antibody. Immunoprecipitated and input samples were loaded on 12% 
SDS polyacrilamide gel and blotted with an anti-Peroxidase Anti Peroxidase (PAP) antibody to identify the 
external part of the TAP tag. As negative control (C-), proteins were incubated with beads without antibody. (D) 
Co-immunoprecipitation of endogenous PED with exogenous Rac-AU5 tagged. The experimental procedure is 
indicated above. (E) Co-immunoprecipitation between endogenous PED and Rac1. Samples from A459 wild type 
cells were immunoprecipitated with anti-PED antibody. 
 
PED affects Rac1 activation. In order to investigate the effects of PED on Rac1 activation, 
A459 cells were transfected with PED-MYC cDNA or control vector. After 24 h cells were 
serum starved for 16 h and then treated with 20% FBS for 5 or 15 min. The activity of Rac1 
was assessed using the p21-binding domain (CRIB) of p21-activated kinase 1 (PAK1) in a 
GST-pull down assay. As shown in fig. 28A, after 5 min of stimulation a larger amount of 
Rac1-GTP could be observed in PED overexpressing cells, compared to the control cells, 
transfected with an empty vector. This activation decreased after 15 min. Similar results 
could be obtained upon EGF stimulation, a Rac1 specific activator, with a similar kinetics 
(data not shown).  
 
Mechanisms of PED-mediated Rac1 activation. The removal of bound GDP and the 
subsequent loading of GTP are catalyzed by guanine nucleotide exchange factors (GEFs 
proteins). We therefore asked whether PED could act as a scaffold protein in Rac1 activation 
by promoting the interaction between Rac1 and its GEFs. A459 cells were transfected with 
PED-MYC cDNA, starved for 24 h and then incubated for 16 h with 100 μM of NSC23766, a 
Rac1 GTPase specific inhibitor that inhibits GEFs binding to Rac1 (35). Subsequently cells 
were treated with 20% FBS for 5 min and Rac1-GTP pull down assay was performed. As 
observed above, PED overexpression increased Rac1 activation upon serum stimulation. 
However, this effect was inhibited by pretreating cells with NSC23766 (fig. 28B), suggesting 
that Rac1 is activated by PED through a mechanism involving GEFs action.  
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Role of PED in AKT-mediated Rac1 phosphorylation. AKT is serine/threonine kinase 
downstream PTEN/PI3K pathway involved in many cellular processes, e.g. survival, 
apoptosis and migration. AKT phosphorylates Rac1 on Ser71 and this process inhibits its 
GTP-loading. Because PED interferes with Rac1-GTP loading, we asked whether this effect 
was mediated through the regulation of Rac1 phosphorylation on Ser71. To this aim, A459 
cells were transfected with control vector or PED-MYC cDNA. After 24 h, the cells were 
serum starved and then treated for 5 min with 20% FBS. As shown in fig. 2C, PED 
overexpression resulted in a strong reduction of serum mediated Rac1 phosphorylation in 
Ser71. Similar results were obtained with EGF stimulation (data not shown). To further 
confirm this observation, we evaluated basal Rac1 phosphorylation levels in A459 cells 
transfected with a constitutive active AKT (AKT D+) and PED-MYC cDNAs (fig. 28D). AKT 
D+ increased Rac1-Ser71 phosphorylation, while co-transfection of AKT D+ and PED-MYC 
cDNAs resulted in a reduction of Rac1 phosphorylation levels. These results suggest that 
PED can enhance Rac1-GTP bound state by interfering with AKT-mediated Rac1 
phosphorylation. 
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Figure 28. PED regulates Rac1-GTP loading. (A) A459 cells were transfected with 2 μg empty vector as control 
or 2 μg PED-MYC cDNA as indicated. After 24 h cells were serum starved and then treated for 5 and 15 min with 
20% FBS respectively. Rac1-GTP pull down assay was performed as described in the methods section. The  
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amounts of total Rac1 and Rac1-GTP were estimated by immunoblotting with Rac1. (B) Rac1-GTP pull down 
assay with PED cDNA overexpression and 20% FBS stimulation or 100 μM NSC23766 pretreatment for 16 h. (C) 
PED cDNA expression inhibits AKT-induced Ser71 Rac1 phosphorylation upon serum stimulation. A459 cells were 
transfected with 2 µg of PED cDNA or control vector, then starved for 16 h and treated as indicated. (D) 
Evaluation of Rac1 phosphorylation levels upon transfection with 2 µg of PED-MYC or AKT D+. The total amount 
of transfected plasmids is normalized with co-transfection of empty vector.  
 
Effects of Rac1 activation on PED phosphorylation status. PED needs to be phosphorylated 
in Ser104 and Ser116 to be recruited to the DISC and to inhibit the apoptotic process. 
Furthermore, PED in its non-phosphorylated status can bind and sequester ERK 1/2 into 
cytosol . We asked whether Rac1 could alter PED phosphorylation status and thus its 
function. To this aim, we transfected A459 cells wild type Rac or constitutively active Rac 
(RacQL) cDNAs. Interestingly, PED-Ser104 phosphorylation was increased upon transfection 
of wild type Rac and more strongly by RacQL compared to control (fig. 29A). Serine116 
phosphorylation was not modified (data not shown). Furthermore, Ser104-PED 
phosphorylation was also upregulated by transfection with another constitutively active Rac 
(Rac12V)  and with Vav1 overexpression, one of Rac1 GEFs (fig. 29B). Because PKC is the 
major kinase involved in PED-Ser104 phosphorylation, we investigated whether Rac1 may 
regulate PED phosphorylation through PKC. To this aim, A459 cells were transfected with 
constitutively active Rac and then treated with 108 nM Ro-32-0432, a cell-permeable and 
selective PKC inhibitor. PED phosphorylation levels on serine 104 were evaluated by blotting 
with specific anti-phospho-serine 104 PED antibody. As shown in figure 29C, RacQL-
mediated PED phosphorylation was completely abolished when cells were treated with the 
PKC inhibitor. These results suggest that Rac1 augments PED phosphorylation on serine 
104 by regulation of PKC activity.  
 
Role of PED and Rac1 interaction on ERK 1/2 activation. In order to investigate the 
downstream effects of PED and Rac1 interaction, we investigated ERK 1/2 pathway. PED 
can promote ERK 1/2 phosphorylation and activation, but retaining them into cytosol avoiding 
their nuclear translocation. The mechanism by which PED allows ERK 1/2 phosphorylation is  
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not clear yet. Rac1 activation leads to ERK 1/2 phosphorylation through a pathway involving 
PAK1-MEK1-ERK1/2. To determine the effect of PED and Rac1 interaction on ERK 1/2 
activation, we transfected A459 cells with control vector, PED-MYC or RacQL cDNAs and 
then evaluated the downstream effects on ERK 1/2 phosphorylation. PED and RacQL alone 
were able to activate ERK 1/2. Interestingly, when PED and RacQL were co-transfected the 
levels of ERK 1/2 phosphorylation were even stronger (fig. 29D). As previously described, we 
found that PED transfection resulted in an inhibitory effect on ERK 1/2 nuclear translocation, 
as attested by the reduction of the phosphorylation of their nuclear substrate ELK1 (fig. 29D). 
On the contrary when PED was overexpressed together with RacQL, ELK1 phosphorylation 
was stronger compared to control. This effect was probably due to the Rac1-induced 
phosphorylation on serine 104. To this aim, we generated a mutant PED protein which could 
not be phosphorylated in Ser104 (S104G PED). Transfection of S104G PED mutant, alone or 
co-transfected with RacQL, abolished the phosphorylation of ELK1 (fig. 29D). These results 
suggest that PED, upon Rac-induced Ser104 phosphorylation, lost its capability to retain ERK 
1/2 into cytosol, while its unphosphorylable mutant S104G blocked ERK 1/2 into cytosol, 
even in presence of constitutively active Rac mutant. 
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 Figure 29. Rac1 activation induces PED-Ser104 phosphorylation. (A) A459 cells were transfected with control 
vector, Rac and RacQL. Overexpression of constitutively active Rac resulted in a strong increase of Ser104–PED 
phosphorylation, as attested by immunoblotting with specific Ser104–PED antibody. (B) Confirmation of Rac-
induced PED phosphorylation using another active mutant of Rac (12V) and with Vav1 overexpression. A459 
cells were transfected with control vector, Rac, RacQL, Rac12V and Vav1 respectively and then Ser104–PED 
phosphorylation was evaluated. (C) A459 cells were transfected with 2 μg of RacQL and then treated with 108 nM 
PKC inhibitor Ro-32-0432 for 16 h. PKC inhibition resulted in abolishment of Rac-induced Ser104–PED 
phosphorylation. (D) A459 cells were transfected with control vector, PED, PED S104G or RacQL. Then cells 
were starved for 16 h and treated with 20% FBS. Expression of PED and Rac-QL resulted in an increase of ERK 
1/2 phosphorylation and Elk1 activation upon serum stimulation, while Elk1 phosphorylation, but not ERK 1/2 
phosphorylation, was abrogated by transfection of unphosphorylable PED mutant S104G, even with RacQL, 
indicating that ERK 1/2 were restrained into cytosol.  
Role of PED on cell migration. One of the most important effects of the activation of ERK1/2 
pathway is regulation of cellular migration and invasion. For this reason we asked wheter 
PED/Rac1 interaction was involved in these phenomena. Interestingly, overexpression of 
PED-MYC resulted in increased migration and invasion of A459 cells. The effect was similar 
to that obtained with constitutive active Rac (fig. 30A and 30B). When PED-MYC and RacQL 
were cotransfected, the effects on cell migration and invasion were even stronger than 
controls. Similar results were obtained by transfecting the same constructs into HeLa cells 
(data not shown).  Moreover, unphosphorylable S104G PED mutant was able to inhibit both 
cell migration and invasion (fig. 30A), demonstrating the importance of Rac1-induced PED  
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phosphorylation in serine 104. Indeed S104G PED mutant was able to bind ERK 1/2, 
sequestrate them into cytosol, not allowing them to migrate into nucleus and promote cell 
migration and invasion. On the other hand, A459 PED knock-down clones had reduced 
migratory and invasive capabilities (fig. 30B). Furthermore, PED knock-down clones showed 
also a reduced wound healing capability, compared to control cells (fig. 30C). To determine 
the pathway involved in the regulation of PED-mediated migration and invasion, PED 
overexpressing A459 cells were treated with 100 µM Rac1 inhibitor NSC23766 or 108 nM 
PKC inhibitor Ro-32-0432 for 16 h. PED-MYC transfected cells lost their capability to migrate 
and invade upon treatment with inhibitors (fig. 31A), demonstrating that PED requires Rac1 
and PKC activity to promote migration and invasion. To finally prove Rac1 involvement in 
PED-mediated cell migration and invasion, we down-regulated Rac1 with the transfection of 
specific siRNAs. Upon Rac1 downregulation, PED could not promote cell migration and 
invasion anymore (fig. 31B). These results show for the first time that PED expression 
promote cell migration and invasion through a mechanism involving the activation of Rac1, 
PKC and ERK1/2. 
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Figure 30. Effects of PED and Rac1 interaction on cell migration and invasion. (A) A459 cells were transfected 
with control vector, PED, PED S104G or mutant RacQL, and transwell migration and invasion assay was 
performed as described above. (B) A459-PED KO clones, obtained with transfection of specific PEDshRNA 
vector and then selected with 2.5 µg/ml of Puromycin. A459-PED KO clones showed a reduction of migration and 
invasion upon serum stimulation, compared to control cells expressing Scrambled shRNA (control). (C) Wound 
healing assay of A459 shScrambled cells and PED shRNA clones (Sh1 and Sh2). Cells were grown to confluence 
and then wound was performed using a pipette tip. Then cells were incubated and grown for 24 h.  
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Figure 5. Pathways of PED-mediated migration and invasion. (A) A459 cells were transfected with control vector 
or PED cDNA. Then cells were plated on transwell chambers to perform migration and invasion assays and 
treated with Rac1 and PKC inhibitors (NSC23766 and Ro-32-0432 respectively). Migrated cells were evaluated 
24 h later. Cells were stained in 25% methanol and 0.1% crystal violet. Then it was eluited with 1% SDS and the 
migration rate was established by reading absorbance at λ 570 nm. (B) A459 cells were transfected with control 
vector, PED-MYC and Rac1-siRNAs. Rac1 downregulation was evaluated by immunoblotting with Rac1 antibody. 
Transwell chambers were used to perform migration and invasion assays. 105 cells were plated onto the upper 
chamber of tranwell and cells were incubated for 24 h. Rac1 downregulation blocked PED-mediated migration 
and invasion. 
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DISCUSSION 
There is much evidence implicating an important role for PED in human cancer. PED, being 
a member of DED protein family (24), induces resistance to TRAIL, FasL, TNFα-mediated 
death in cancer cells (22-30), making therapy often ineffective. Increased expression of DED 
family members with anti-apoptotic functions, such as PED, represents a possible 
mechanism by which tumor cells escape apoptosis. PED acts primarily by preventing the 
interaction between the adaptor molecule, FADD, and procaspase-8. We have reported that 
PED inhibits the anti-apoptotic signal of death receptors in many different cell types, 
including breast carcinoma and glioma, in which it is overexpressed.  
Lung tumors are among the most aggressive types of cancer and are frequently resistant to 
drug-induced cell death. 80% of lung cancers are of the NSCLC type. Advances in standard 
treatment for this tumor, such as surgery, radiotherapy, and chemotherapy, have not 
significantly increased patient survival. Thus, novel treatment strategies are urgently needed 
to improve the clinical management of this serious disease. Recent studies have 
demonstrated that targeting TNF superfamily death receptors is a promising strategy for the 
treatment of cancer. Apoptosis-based anti-cancer therapies are designed to achieve tumor 
eradication through the use of death-inducing molecules capable of activating the apoptotic 
program selectively in neoplastic cells. Due to its specific toxicity for transformed cells, 
recombinant forms of TRAIL are among the most promising apoptosis-based anti-tumor 
agents. In fact, a number of biotech and pharmaceutical companies developed recombinant 
TRAIL/Apo2L as well as humanized agonistic mAb targeting TRAIL-R1 or TRAIL-R2 that are 
currently being evaluated in Phase I and Phase II clinical trails. Mice that are genetically 
deficient in the TRAIL gene, exhibit increased susceptibility to experimental and spontaneous 
tumors, suggesting an important role of endogenous TRAIL in tumor surveillance. However, 
in a number of patients, tumor cells evade death signals generated by drugs through the 
activation of effective anti-apoptotic mechanisms. We demonstrated that PED is 
overexpressed in lung cancer tissue obtained from 27 NSCLC-affected patients.  
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Interestingly, TNM staging revealed that PED expression is greater during the first phase of  
the disease (T1) than in T2 lesions. The analysis of PED expression in pre-malignant lesions, 
such as metaplastic bronchial lesions, could shed light on the role of PED in tumor initiation, 
progression and invasiveness. This study shows that PED regulates the susceptibility to 
TRAIL-induced death in lung cancer cells. In fact, while the levels of PED differs significantly 
in CALU-1 (TRAIL-insensitive) and H460 (TRAIL-sensitive) cells, the levels of the other 
signaling components (such as TRAIL receptors caspases, and FADD) were comparable. 
Modulation of the sensitivity to TRAIL by PED was confirmed by down regulating PED 
expression with PED siRNA: when transfected, the otherwise TRAIL-insensitive CALU-1 
cells became susceptible to this cytotoxic cytokine. Moreover, PED overexpression in H460 
cells was able to change their phenotype from TRAIL-sensitive to TRAIL- insensitive. 
Because resistance of different tumors may be mediated by diverse survival mechanisms, 
we investigated the role of c-FLIP in TRAIL resistance by down-regulation of c-FLIP 
expression with a specific siRNA. As already observed in other tumor types such as glioma 
and B-cell chronic leukemia, the effects of PED are prevalent over those mediated by c-FLIP 
for sensitivity to TRAIL. Thus, it is possible that c-FLIP and PED contribute differently, 
depending to the cell type or tumor type to induce resistance to TRAIL. Our data thus 
demonstrate that PED plays a major role in TRAIL resistance in NSCLC. Although PED 
expression was completely and specifically inhibited by the transfection with PED siRNA 
duplex, TRAIL sensitivity was not fully recovered. These results suggest that it is likely that 
there might be alternative mechanisms for TRAIL resistance.  
Thus, the overexpression of a gene involved in resistance to TRAIL could be important for 
responsiveness to chemotherapy. Since expression levels of PED are a focal point for the 
regulation of apoptosis, PED represents a key target for treatment of cancer. 
We furthermore analyzed the molecular mechanisms by which PED expression is regulated. 
In collaboration with the group of Theo Rein, Max Planck Institute of Psychiatry, Munich, 
Germany,  we searched for vitamin D3-regulated targets in the proteome of human brain- 
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derived cells. Up-regulation of PED was the most prominent feature on the used antibody 
array. We investigated this up-regulation further and conclude from our experiments with 
different cell lines (human Non Small cell Lung Cancer A549 cell line, with low endogenous 
PED levels) that vitamin D3 leads to an increase in promoter activity of PED already after 3-6 
h and with a little delay to an increase in protein phosphorylation after 6h, most likely via 
activation of AKT1, which is known to phosphorylate PED. The increase in mRNA and the 
protein stabilization through phosphorylation in combination lead to an increase in total PED 
protein level after 12h. Our finding of increased AKT1 activity after vitamin D3 exposure not 
only provides a potential mechanism for activation of PED, but also adds another pathway 
through which vitamin D3 exerts anti-apoptotic effects. Our discovery that PED is strongly 
responsive to vitamin D3 potentially links vitamin D3 to any of the actions of PED. Although 
extensive work needs to be done to test the degree of overlapping activities, we already 
showed in this work that vitamin D3 significantly affected apoptosis and cell survival in A549 
cells in a PED-dependent manner. 
Recently, Peacock et al. demonstrated that PTEN can regulate PED phosphorylation and 
activity in an AKT-dependent manner, and thus modulate the ability of Bcl-2 to suppress Fas-
induced apoptosis (36). A new role for PED in cancer was then proposed by Bartholomeusz 
et el. by suggesting a mechanism involving activation of ERK 1/2 pathway and induction of 
autophagy (37). The ability of PED to bind ERK 1/2 was the focus of many studies that 
indicated that PED can restrain ERK 1/2 within the cytosol, avoid their nuclear translocation 
and this way block the nuclear effects mediated by these signaling molecules, among them 
transcription, migration, invasion. Moreover, PED, through the control of activated-ERK1/2 
localization, can act as a tumor suppressor gene in inducing senescence and reducing the 
transforming effects of oncogenic Ras (38). Further evidence that PED is connected to ERK 
activation derives from its capability to bind RSK2 in a phosphorylation-regulated manner 
and act as a scaffold protein to strengthen its role in ERK activation (39). The emerging 
scenario is complex, with a single protein involved in many cellular pathways, varying from 
apoptosis to cell migration, invasion, autophagy, senescence, cell signaling. In order to give  
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new insights in PED’s role in cancer, we aimed to discover new interactors of PED. We 
performed a generic purification method for protein complexes characterization, the tandem 
affinity purification method. This method has two purification steps, obtained with IgG-
Agarose and Calmodulin chromatographic supports, which allow high binding specificity of 
interaction partners. Upon mass spectrometry analysis of final eluition, we identified several 
new candidate partners of PED, one of which was Rac1. We first confirmed the interaction 
between PED and Rac1 through independent immunoprecipitation experiments, using both 
exogenous and endogenous proteins. It was interesting to note that phosphorylation status of 
PED did not interfere with its interaction with Rac1. Indeed, unphosphorylable Ser104 and 
Ser116 PED mutants still interacted with Rac1 (not shown). In order to investigate the effect of 
PED on Rac1 GDP/GTP bound state, we performed a GST-pull down assay using the p21-
binding domain (CRIB) of p21-activated kinase 1 (PAK1) to isolate the active GTP-bound 
Rac1 from the total extract. We demonstrated that PED augmented GTP-bound state upon 
stimulation with both unspecific stimulus of 20% FBS or specific Rac1 activator as EGF (not 
shown) in a mechanism involving GEFs action. Downregulation of PED, obtained with 
specific PED-siRNAs, did not significantly alter GDP/GTP exchange compared to control 
samples (data not shown). PED did not act as a scaffold protein in promoting GEFs-Rac1 
binding, since in co-immunoprecipitation experiments, PED could not bind neither Tiam1 nor 
TrioN, two of the most abundant Rac1 GEFs. Moreover, we did not identify any GEFs from 
tandem affinity purification analysis and mass spectrometry experiments that bind to the PED 
complex. Our data show that PED was able to inhibit AKT-mediated Rac1 Ser71 
phosphorylation. It was previously shown that this phosphorylation inhibits GEFs binding to 
Rac1, thus preventing Rac1 activation (35). To better elucidate this point, we generated two 
stable PED knock out (KO) clones with PED-specific shRNA plasmid vectors and then we 
evaluated Rac1 phosphorylation by blotting with phospho-serine 71 Rac1 antibody. PED 
downregulation resulted in 30% increase in Rac1 phosphorylation, compared to control cells 
(not shown). The mechanism of PED effects on Rac1 phosphorylation is not clear yet. Since  
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it was reported that AKT/PI3K pathway is involved in motility of tumor cells and AKT has 
negative regulatory role on Rac1 (35), we hypothesized that PED promotes GTP loading to 
Rac1, by reducing AKT inhibitory effects on Rac1.  
Interestingly, PED and Rac1 interefered with each other’s function once bound together. In 
facts, when Rac1 is active, promotes PED Ser104 phosphorylation, as shown with two 
different Rac constitutively active mutants (RacQL, Rac12V) or with the overexpression of 
Vav1. This mechanism involves PKC activation. In facts, treatment with specific PKC 
inhibitors completely abolished  PED Ser104 phosphorylation. The mechanism by which Rac1 
promotes PKC-dependent PED phosphorylation is under investigation in our lab.  
PED and Rac1 are involved in many cellular process. To understand the biological meaning 
of their interaction we focused on the regulation of ERK 1/2 activation status as well as their 
cellular localization. We observed that co-expression of PED and constitutively active Rac 
induced a strong ERKs phosphorylation as well as Elk-1 activation, indicating that ERKs 
were able to translocate from the cytosol into the nucleus. We propose that PED alone 
coadiuvates Rac1-mediated ERKs activation and the expression of active Rac facilitates 
PED phosphorylation on Ser104 and the consequent release of ERKs. Furthermore, in this 
study we demonstrate that PED is involved in promoting cell migration and invasion. 
Previous findings described that PED mediated inhibition of cell migration/invasion. Our data 
suggest that Rac1’s effects on PED phosphorylation determine a reduction of PED’s 
inhibitory role of ERK 1/2 nuclear translocation, which is required to promote 
migration/invasion. We propose a model in which when Rac1 is activated, PED 
phosphorylation on Ser104 is increased and its binding with ERK 1/2 is reduced. This results 
in abrogation of its regulatory role on ERK 1/2 (involving nuclear migration, cell invasion and 
proliferation). 
Besides Rac1-induced effects on PED phosphorylation, we did not observe any interference 
in PED-mediated TRAIL resistance (our unpublished observations). Ramos et al. previously 
reported that PED activates ERK MAP Kinase through a Ras-dependent pathway (38). PED- 
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Rac1 interaction gives a new explanation of how PED can mediate its effects on MAPK 
signaling. Here we demonstrate that regulation of PED phosphorylation can modify its ability 
to promote or repress cell migration and invasion. 
Our findings about PED interactome demonstrate that PED overexpression is linked to 
cancer not only because of an anti-apoptotic role but also because this promotes migration 
and invasion of malignant cells. This protein might result, therefore, to be a good target for 
anti-neoplastic therapy. 
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